<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Gut Microbes</journal-id><journal-id journal-id-type="iso-abbrev">Gut Microbes</journal-id><journal-title-group><journal-title>Gut Microbes</journal-title></journal-title-group><issn pub-type="ppub">1949-0976</issn><issn pub-type="epub">1949-0984</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40397816</article-id><article-id pub-id-type="pmc">PMC12101587</article-id>
<article-id pub-id-type="doi">10.1080/19490976.2025.2501186</article-id><article-id pub-id-type="publisher-id">2501186</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>ILSI Europe perspective review: site-specific microbiota changes during pregnancy associated with biological consequences and clinical outcomes: opportunities for probiotic interventions</article-title><alt-title alt-title-type="left-running-head">E. FLORES VENTURA ET AL.</alt-title><alt-title alt-title-type="right-running-head">GUT MICROBES</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Flores Ventura</surname><given-names>Eduard</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7523-7238</contrib-id><name><surname>Lane</surname><given-names>Jonathan A.</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>b</sup>
</xref><xref rid="an0002" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5224-1215</contrib-id><name><surname>Turjeman</surname><given-names>Sondra</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8012-4051</contrib-id><name><surname>Vidra</surname><given-names>Nikoletta</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5983-5569</contrib-id><name><surname>Weiss</surname><given-names>Gisela Adrienne</given-names></name><xref rid="aff0005" ref-type="aff">
<sup>e</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gross</surname><given-names>Gabriele</given-names></name><xref rid="aff0006" ref-type="aff">
<sup>f</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0003-4867-8654</contrib-id><name><surname>Chang</surname><given-names>Ching-Yu</given-names></name><xref rid="aff0007" ref-type="aff">
<sup>g</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7738-1337</contrib-id><name><surname>Koren</surname><given-names>Omry</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>c</sup>
</xref><xref rid="aff0008" ref-type="aff">
<sup>h</sup>
</xref></contrib><aff id="aff0001"><label>a</label>Department of Biotechnology, <institution-wrap><institution>Institute of Agrochemistry and Food Technology &#x02013; Spanish National Research Council (IATA-CSIC)</institution></institution-wrap>, <city>Valencia</city>, <country>Spain</country></aff><aff id="aff0002"><label>b</label>Health and Happiness (H &#x00026; H) Group, H &#x00026; H Research, <institution-wrap><institution>National Food Innovation Hub, Teagasc Moorepark</institution></institution-wrap>, <city>Fermoy, Co., Cork</city>, <country>Ireland</country></aff><aff id="aff0003"><label>c</label>Azrieli Faculty of Medicine, <institution-wrap><institution>Bar-Ilan University</institution></institution-wrap>, <city>Safed</city>, <country>Israel</country></aff><aff id="aff0004"><label>d</label>Science Department, <institution-wrap><institution>Yakult Europe</institution></institution-wrap>, <city>Almere</city>, <country>The Netherlands</country></aff><aff id="aff0005"><label>e</label>Department Innovation, <institution-wrap><institution>Yili Innovation Center Europe</institution></institution-wrap>, <city>Wageningen</city>, <country>The Netherlands</country></aff><aff id="aff0006"><label>f</label>Mead Johnson Nutrition Institute/Reckitt, R &#x00026; D, <institution-wrap><institution>Nutrition Science Platforms</institution></institution-wrap>, <city>Nijmegen</city>, <country>The Netherlands</country></aff><aff id="aff0007"><label>g</label>International Life Science Institute, International Life Science Institute, <institution-wrap><institution>European Branch</institution></institution-wrap>, <city>Brussels</city>, <country>Belgium</country></aff><aff id="aff0008"><label>h</label><institution-wrap><institution>Kyung Hee University</institution></institution-wrap>, <city>Seoul</city>, <country>The Republic of Korea</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Ching-Yu Chang <email xlink:href="mailto:publications@ilsieurope.be">publications@ilsieurope.be</email> International Life Science Institute, International Life Science Institute, <addr-line>European Branch</addr-line>, Avenue E. Mounier 83, Box 6. B-1200, <city>Brussels</city>, <country>Belgium</country></corresp><corresp id="an0002">Jonathan A. Lane <email xlink:href="mailto:jonathan@hh.global">jonathan@hh.global</email> Health and Happiness (H &#x00026; H) Group, H &#x00026; H Research, National Food Innovation Hub, <addr-line>Teagasc Moorepark</addr-line>, <city>Fermoy, Co., Cork</city> P61K202, <country>Ireland</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><elocation-id seq="189">2501186</elocation-id><pub-history><event event-type="tagger"><event-desc>Integra</event-desc><date><day>21</day><month>5</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>21</day><month>5</month><year>2025</year></date></event><event event-type="received"><date><day>05</day><month>12</month><year>2024</year></date></event><event event-type="revised"><date><day>11</day><month>4</month><year>2025</year></date></event><event event-type="accepted"><date><day>29</day><month>4</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2025 ILSI Europe. Published with license by Taylor &#x00026; Francis Group, LLC.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>ILSI Europe</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="KGMI_17_2501186.pdf"/><abstract><title>ABSTRACT</title><p>Pregnancy induces notable alterations in the gut, vaginal, and oral microbiota driven by hormonal, immune, metabolic, dietary, and environmental factors. During pregnancy, the gut microbiota is characterized by increased proportions of the genus <italic toggle="yes">Bifidobacterium</italic> and the phyla Pseudomonadota (formerly Proteobacteria) and Actinomycetota (formerly Actinobacteria). These changes occur alongside reduced alpha diversity and greater beta diversity, changes that influence maternal metabolism and fetal development. Shifts in gut and oral microbiota have been associated with complications such as preterm birth (PTB), pre-eclampsia, and gestational diabetes (GDM), though patterns are sometimes inconsistent. The vaginal microbiota remains <italic toggle="yes">Lactobacillus</italic>-dominant during pregnancy, with reduced diversity leading to reduced risk of pathogenic infection and increased diversity has been linked with a higher risk of PTB. Hormonal changes also affect the oral microbiota, potentially increasing pathogenic species and contributing to adverse outcomes like PTB. Probiotic supplementation during pregnancy has significant potential to reduce adverse pregnancy outcomes; however, clinical studies are still limited. Probiotics may be effective in alleviating maternal constipation and lead to lower PTB risk, particularly by modulating the vaginal microbiota, but they have limited impact on GDM. In the context of maternal mental health, some studies suggest benefits of probiotics in reducing anxiety, but effects on depression are inconclusive. This perspective examines how pregnancy-related microbial shifts, both natural and probiotic-induced, affect maternal and fetal health and highlights potential opportunities for the innovative use of probiotics during the gestation period.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Maternal health</kwd><kwd>probiotics</kwd><kwd>pregnancy</kwd><kwd>gut microbiota</kwd><kwd>oral microbiota</kwd><kwd>vaginal microbiota</kwd><kwd>supplementation</kwd><kwd>microbiome</kwd></kwd-group><support-group><funding-group><award-group><funding-source>
<institution-wrap><institution>Biostime Institute Nutrition &#x00026; Care (BINC) research</institution></institution-wrap>
</funding-source></award-group><funding-statement>E.F.V thanks to a Predoctoral grant awarded by the Spanish Ministry of Science and Innovation and the European Social Fund Plus (ESF+) for the training of doctors within the framework of the State Plan for Scientific, Technical and Innovation Research 2021&#x02013;2023. [ref. CEX2021-001189-S-20-1]. E.F.V, S.T., and O.K. are supported by a Biostime Institute Nutrition &#x00026; Care (BINC) research grant.</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="1"/><ref-count count="73"/><page-count count="1"/><word-count count="7682"/></counts></article-meta></front><body><sec sec-type="intro" disp-level="1" id="s0001"><label>1.</label><title>Introduction</title><p>The maternal microbiota, defined by the International Scientific Association for Probiotics and Prebiotics (ISAPP) as &#x0201c;the microorganisms themselves: bacteria, archaea, lower and higher eukaryotes, and viruses in a defined environment&#x0201d;, in this case, within the mother, undergoes significant changes during pregnancy. These changes can influence both maternal and fetal health.<sup><xref rid="cit0001" ref-type="bibr">1&#x02013;3</xref></sup> Alterations in maternal gut, vaginal, and oral microbiota during the first, second, and third trimesters have been extensively studied elsewhere, and biological consequences and clinical outcomes, such as gestational diabetes mellitus (GDM), pre-term birth (PTB), and pre-eclampsia (PE) have been associated with such changes.<sup><xref rid="cit0004" ref-type="bibr">4&#x02013;6</xref></sup> Overall, the specific biological mechanisms and microbial taxa involved remain under investigation.</p><p>Microbiome-modulating interventions during pregnancy aim to support healthy biological changes, such as hormonal, immune, and metabolic adjustments that occur during and throughout pregnancy and may significantly prevent adverse pregnancy outcomes. Such interventions can include the use of &#x0201c;biotics&#x0201d;, such as prebiotics, probiotics, and postbiotics, or dietary change. The use of commercially available probiotic(s) during pregnancy is one such interventions that has been clinically studied, however with inconsistent results. Although some studies suggest that probiotics, defined as &#x0201c;live microorganisms that, when administered in adequate amounts, confer a health benefit on the host&#x0201d;,<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup> might improve pregnancy outcomes, these associations are based on limited and primarily inferential evidence. The reasons for variability in outcomes across studies can be associated with clinical study design, use of different probiotic strain(s) and doses, and/or the lack of precision interventions such as not factoring when/how a probiotic should be consumed or how host genetics (e.g. secretor status) may influence colonization potential.<sup><xref rid="cit0007" ref-type="bibr">7</xref>,<xref rid="cit0008" ref-type="bibr">8</xref></sup> The efficacy and safety of probiotics can vary significantly due to strain-specific effects. Different strains of the same species can cause varied clinical outcomes, underscoring the complexity of recommending probiotics for specific uses.<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> Genetic variation between strains influences key characteristics such as their metabolic activities, their ability to adhere to epithelial cells, and their immunomodulatory properties.<sup><xref rid="cit0010" ref-type="bibr">10</xref></sup> These factors can directly impact the effectiveness and safety profile of probiotic interventions. Moreover, the effective dosage of probiotics and time of prescription are highly heterogeneous, influenced by variables such as the viability of the strain, the formulation used, and the individual&#x02019;s existing commensal microbial composition.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup> This variability suggests that a personalized approach might be necessary to optimize probiotic interventions, further complicating standardization and clinical application.</p><p>Taken together, these challenges highlight the need for a review that not only maps the knowledge on microbial shifts during pregnancy and their relationship with maternal and fetal health but also examines probiotic efficacy and safety in this context. We aimed to identify gaps and opportunities, along with exploring the potential for personalized probiotic interventions. By understanding these dynamics, we can better design and utilize probiotics to enhance gestational health. Rather than systematically reviewing all existing data, this perspective aims to provide an overview of emerging trends and potential probiotic interventions during pregnancy, offering a targeted and innovative synthesis. We then give a perspective on a more targeted approach to the use of probiotics during pregnancy that can support future clinical study design and the subsequent use of probiotics to prevent adverse pregnancy outcomes.</p></sec><sec disp-level="1" id="s0002"><label>2.</label><title>Maternal microbiota changes and biological consequences associated with clinical outcomes during pregnancy</title><p>Major changes in microbial communities during pregnancy and their implications for maternal or fetal health are highlighted in <xref rid="f0001" ref-type="fig">Figure 1</xref>. During pregnancy, the gut microbiota undergoes significant changes between the first and third trimester, influenced by physiological factors such as increased progesterone levels.<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> In the first trimester, a lower abundance of <italic toggle="yes">Bifidobacterium</italic> and <italic toggle="yes">Streptococcus</italic> has been associated with PTB. Meanwhile, PE and GDM have been associated with decreased abundance of short-chain fatty acid (SCFA)-producing bacteria and altered metabolic pathways. In the third trimester, pregnant women display a higher proportion of <italic toggle="yes">Bifidobacterium</italic>, as well as the phyla Pseudomonadota (formerly Proteobacteria) and Actinomycetota (formerly Actinobacteria). This shift is accompanied by reduced alpha diversity, increased beta diversity and a rise in opportunistic pathogens compared to the first trimester. These microbiota alterations impact maternal metabolism and fetal organ development.<sup><xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0014" ref-type="bibr">14</xref></sup> Changes in the gut microbiota during the third trimester have been linked via statistical inference to PTB, PE, and GDM, characterized by lower diversity and specific bacterial imbalances.<sup><xref rid="cit0015" ref-type="bibr">15&#x02013;17</xref></sup>
<fig position="float" id="f0001" fig-type="figure"><label>Figure 1.</label><caption><p>Maternal microbiota shifts during pregnancy and their clinical implications. Overview of microbiota changes in the oral, vaginal, and gut compartments during pregnancy, and their potential impact on maternal and foetal outcomes, including preterm birth, infection risk, metabolic health, and gestational complications. Symbols indicate: Blue shield, microbial shifts associated with beneficial health effects; yellow triangle, microbial shifts associated with adverse health effects; green boxes, changes in endogenous maternal microbiota; blue boxes, associated biological implications; capsule symbol, potential effects of probiotic interventions. Figure created with BioRender.com.&#x000a9; Flores, V.E. (2025). Retrieved from <ext-link xlink:href="https://BioRender.com/p25dwhp" ext-link-type="uri">https://BioRender.com/p25dwhp</ext-link>.</p></caption><alternatives><graphic xlink:href="KGMI_A_2501186_F0001_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="KGMI_A_2501186_F0001_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>Also, the vaginal microbiota changes significantly throughout pregnancy toward a predominance of <italic toggle="yes">Lactobacillus spp</italic>., including <italic toggle="yes">Lactobacillus crispatus</italic>, <italic toggle="yes">Lactobacillus iners</italic>, <italic toggle="yes">Lactobacillus gasseri</italic>, and <italic toggle="yes">Lactobacillus jensenii</italic>, which produce lactic acid to inhibit pathogen growth. This shift results in reduced microbial diversity, which is crucial for preventing bacterial vaginosis and sexually transmitted infections. Postpartum, microbial diversity increases, and <italic toggle="yes">Lactobacillus</italic> abundance decreases.<sup><xref rid="cit0018" ref-type="bibr">18</xref>,<xref rid="cit0019" ref-type="bibr">19</xref></sup> Additionally, a study that analyzed weekly vaginal samples throughout gestation found that highly diverse vaginal communities and high levels of <italic toggle="yes">Gardnerella</italic> or <italic toggle="yes">Ureaplasma</italic>, combined with low levels of <italic toggle="yes">Lactobacillus</italic>, were associated with increased risk of PTB and proinflammatory cytokine expression in vaginal fluid, which may trigger PTB.<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup></p><p>The oral microbiota, dominated by <italic toggle="yes">Streptococcus spp</italic>., undergoes significant shifts during pregnancy due to hormonal changes, with increases in pathogenic bacteria like <italic toggle="yes">Prevotella intermedia</italic>, <italic toggle="yes">Porphyromonas gingivalis</italic>, and <italic toggle="yes">Fusobacterium nucleatum</italic>.<sup><xref rid="cit0021" ref-type="bibr">21</xref></sup> These shifts, linked to changes in estrogen, progesterone, and other hormones, can lead to adverse pregnancy outcomes by promoting systemic inflammation.<sup><xref rid="cit0022" ref-type="bibr">22</xref></sup> Periodontal disease-associated bacteria such as <italic toggle="yes">F. nucleatum</italic> and <italic toggle="yes">P. gingivalis</italic> are notably linked to PTB and PE,<sup><xref rid="cit0023" ref-type="bibr">23</xref></sup> while oral microbiota with increased abundance of <italic toggle="yes">Neisseria</italic> and <italic toggle="yes">Leptotrichia</italic> are correlated with GDM.<sup><xref rid="cit0024" ref-type="bibr">24</xref></sup></p></sec><sec disp-level="1" id="s0003"><label>3.</label><title>Clinical effects of probiotic interventions during pregnancy</title><sec disp-level="2" id="s0003-s2001"><label>3.1.</label><title>Maternal group B streptococcal (GBS) infection</title><sec disp-level="3" id="s0003-s2001-s3001"><label>3.1.1.</label><title>Summary of key clinical trials</title><p>To date, there have been more than seven clinical studies investigating the impact of probiotics on potential maternal infection during pregnancy, involving over 700 women (<xref rid="t0001" ref-type="table">Table 1</xref>). In these studies, three different probiotic supplements have been used (I) <italic toggle="yes">Lacticaseibacillus rhamnosus</italic> (GR-1&#x000ae;) and <italic toggle="yes">Limosilactobacillus reuteri</italic> (RC-14&#x000ae;), (II) <italic toggle="yes">L. jensenii</italic> (LBV 116&#x02122;), <italic toggle="yes">L. crispatus</italic> (LBV88&#x02122;), <italic toggle="yes">L. rhamnosus</italic> (LBV 96&#x02122;), and <italic toggle="yes">L. gasseri</italic> (LBV 150N&#x02122;), and (III) <italic toggle="yes">Ligilactobacillus salivarius</italic> (CECT 9145).<sup><xref rid="cit0025" ref-type="bibr">25&#x02013;29</xref>,<xref rid="cit0053" ref-type="bibr">53</xref></sup><table-wrap position="float" id="t0001" orientation="landscape"><label>Table 1.</label><caption><p>Tested probiotics in clinical trials during pregnancy.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*" align="left"/><col width="1*" align="center"/><col width="1*" align="center"/><col width="1*" align="left"/><col width="1*" align="center"/><col width="1*" align="left"/><col width="1*" align="left"/><col width="1*" align="left"/><col width="1*" align="left"/><col width="1*" align="left"/></colgroup><thead><tr><th align="left">Probiotic strains tested in clinical trials during pregnancy</th><th align="center">Sample size (Placebo/Probiotic)</th><th align="center">Dose<break/>(CFU)</th><th align="center">Trimester of adm</th><th colspan="2" align="center">Duration and type of adm</th><th align="center">Microbiota analyzed</th><th align="center">Observed microbiota changes</th><th align="center">Outcomes</th><th align="center">References</th></tr></thead><tbody><tr><td align="left"><bold>GBS Infection</bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td colspan="2" align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left"><italic toggle="yes">L. jensenii</italic> (LBV 116&#x02122;), <italic toggle="yes">L. crispatus</italic> (LBV88&#x02122;), <italic toggle="yes">L. rhamnosus</italic> (LBV 96&#x02122;) and <italic toggle="yes">L. gasseri</italic> (LBV 150GG&#x000ae;)</td><td align="center">41/41</td><td align="center">2 x 10<sup>8</sup></td><td align="left">3rd trimester</td><td align="center">14 d</td><td align="left">Oral</td><td align="left">Vaginal</td><td align="left">No significant vaginal microbiota shifts observed</td><td align="left">Probiotic treatment (63.6% vs. 77.8% persisting GBS positivity after treatment in the verum and placebo groups, respectively.</td><td align="left">Farr et al.,<sup><xref rid="cit0025" ref-type="bibr">25</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (GR-1&#x000ae;) and <italic toggle="yes">L. reuteri</italic> (RC-14&#x000ae;)</td><td align="center">144/148</td><td align="center">1 x 10<sup>8</sup></td><td align="left">1st trimester</td><td align="center">8 wk</td><td align="left">Oral</td><td align="left">Vaginal (Nugent score)</td><td align="left">No improvement in vaginal flora; slight decrease in normal flora in both groups</td><td align="left">The proportion of normal vaginal microbiota decreased from 82.6% to 77.8% in the treatment group and from 79.1 to 74.3% in the placebo group, with no significant difference across groups after intervention.</td><td align="left">Gille et al.,<sup><xref rid="cit0026" ref-type="bibr">26</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (GR-1&#x000ae;) and <italic toggle="yes">L. reuteri</italic> (RC-14&#x000ae;)</td><td align="center">50/49</td><td align="center">1 x 10<sup>8</sup></td><td align="left">2nd trimester</td><td align="center">3 wk</td><td align="left">Oral</td><td align="left">Vaginal and rectal</td><td align="left">&#x02193; GBS colonization: 42.9% (probiotic) vs 18% (placebo)</td><td align="left">The GBS colonization results changed from positive to negative in 21 women in the probiotic group (42.9%) and in nine women in the placebo group (18.0%) during this period.</td><td align="left">Ho et al.,<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (GR-1&#x000ae;) <italic toggle="yes">and L. reuteri</italic> (RC-14&#x000ae;)</td><td align="center">13/19</td><td align="center">1 x 10<sup>8</sup></td><td align="left">3rd trimester</td><td align="center">3 wk</td><td align="left">Oral</td><td align="left">Vaginal</td><td align="left">&#x02191; <italic toggle="yes">Lactobacillus</italic> spp. in those completing &#x02265;14 d; no GBS change</td><td align="left">In the control group of 3/13 participants were GBS negative at the time of their final swab collection. In the probiotics group of 4/19 participants, were GBS negative at the time of their final swab collection. No significant decrease in GBS in their vaginas.</td><td align="left">Olsen et al.,<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. salivarius</italic> (CECT 9145)</td><td align="center">14/25</td><td align="center">9 x 10<sup>10</sup></td><td align="left">2nd trimester</td><td align="center">12 wk</td><td align="left">Oral</td><td align="left">Vaginal &#x00026; Rectal (with sequencing)</td><td align="left">&#x02193; <italic toggle="yes">Streptococcus agalactiae</italic>; &#x02191; <italic toggle="yes">Lactobacillus</italic> dominance (<italic toggle="yes">L. salivarius</italic>) in probiotic group</td><td align="left">72% and 68% of the women in the probiotic group were GBS-negative in the rectal and vaginal samples, respectively.</td><td align="left">Mart&#x000ed;n et al.,<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup></td></tr><tr><td align="left"><bold>Constipation</bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left"><italic toggle="yes">B. bifidum</italic> (W23), <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic> (W52), <italic toggle="yes">B. longum</italic> (W108), <italic toggle="yes">L. casei</italic> (W79), <italic toggle="yes">L. plantarum</italic> (W62) and, <italic toggle="yes">L. rhamnosus</italic> (W71)</td><td align="center">0/20</td><td align="center">4 x 10<sup>9</sup></td><td align="left">2nd trimester</td><td align="center">4 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Post-intervention, defecation frequency significantly increased from 3.1 at baseline to 6.7. A significant decrease in sensation of anorectal obstruction from 90.0% to 45.0%, sensation of incomplete evacuation from 90.0% to 40.0%, straining during defecation from 100% to 65%, episodes of abdominal pain from 60% to 20%, and the presence of reflux episodes from 60% to 20%.</td><td align="left">de Milliano et al.,<sup><xref rid="cit0030" ref-type="bibr">30</xref></sup></td></tr><tr><td align="left">Yoghurt enriched with <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic> (BB-12&#x000ae;) and <italic toggle="yes">L. acidophilus</italic> (LA-5&#x000ae;)<break/>Yoghurts contained <italic toggle="yes">L. bulgaricus</italic> and <italic toggle="yes">S. thermophilus.</italic></td><td align="center">29/28</td><td align="center">4.8 x 10<sup>10</sup></td><td align="left">2nd trimester</td><td align="center">4 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Constipation symptoms including straining, anorectal obstruction, manipulation to facilitate defecation, consistency of stool and colour of stool were improved significantly in both groups. No statical differences between the groups.</td><td align="left">Mirghafourvand et al.,<sup><xref rid="cit0031" ref-type="bibr">31</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (GR-1&#x000ae;) <italic toggle="yes">and L. reuteri</italic> (RC-14&#x000ae;)</td><td align="center">152/152</td><td align="center">2.5 &#x000d7; 10<sup>9</sup> (each strain)</td><td align="left">1st trimester</td><td align="center">26 wk</td><td align="left">Oral</td><td align="left">Vaginal (Nugent and sequencing)</td><td align="left">No change in diversity, bacterial vaginosis rates, or colonization by probiotic strains</td><td align="left">No significant changes, nor differences between groups.</td><td align="left">Husain et al.,<sup><xref rid="cit0032" ref-type="bibr">32</xref></sup></td></tr><tr><td align="left"><bold>Nutrient Status</bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left">Probiotic yoghurt enriched with <italic toggle="yes">L. acidophilus</italic> (LA5) and <italic toggle="yes">B. lactis</italic> (BB12)</td><td align="center">33/37</td><td align="center">1 &#x000d7; 10<sup>7</sup></td><td align="left">3rd trimester</td><td align="center">9 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Consumption of probiotic yogurt resulted in maintaining serum calcium levels compared with the conventional yogurt. Within-group differences in the conventional yogurt group revealed a significant reduction of serum calcium levels. No significant differences were found between the two yogurts in terms of their effects on serum iron, AST and ALT levels.</td><td align="left">Asemi and Esmaillzadeh<sup><xref rid="cit0033" ref-type="bibr">33</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. plantarum</italic> 299v (LP299V&#x000ae;)</td><td align="center">110/118</td><td align="center">1 x 10<sup>10</sup></td><td align="left">1st trimester</td><td align="center">25 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Attenuated decrease in serum ferritin from baseline to week 28 and week 35 and resulted in reduced prevalence of iron deficiency (59% vs 78%, and iron deficiency anemia (7.4% vs 21%, at week 35. Intake of probiotic also resulted in beneficial effects on the soluble transferrin receptor and total body iron at week 35.</td><td align="left">Axling et al.,<sup><xref rid="cit0034" ref-type="bibr">34</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. acidophilus, L. casei, B. bifidum</italic>, and <italic toggle="yes">L. fermentum</italic></td><td align="center">24/24</td><td align="center">2&#x02009;&#x000d7;&#x02009;10<sup>9</sup></td><td align="left">2nd trimester</td><td align="center">6 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Probiotic supplementation significantly decreased fasting plasma glucose, serum insulin levels, and insulin resistance, and significantly increased insulin sensitivity, compared with the placebo. Supplementation also decreased triglycerides, VLDL-cholesterol, and total-/HDL-cholesterol ratio and significantly increased HDL-cholesterol levels compared with the placebo. Furthermore, led to a significant reduction in plasma malondialdehyde, and a significant elevation in plasma nitric oxide and total antioxidant capacity was observed compared with the placebo.</td><td align="left">Babadi et al.,<sup><xref rid="cit0035" ref-type="bibr">35</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. plantarum</italic> 299v (LP299V&#x000ae;) and 5 mg of iron as ferrous lactate.</td><td align="center">0/21</td><td align="center">1 x 10<sup>9</sup></td><td align="left">Not pregnant(reproductive-age women)</td><td align="center">2 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Mean iron absorption from the drink was significantly higher than the iron absorption from the control drink.</td><td align="left">Hoppe et al.,<sup><xref rid="cit0036" ref-type="bibr">36</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. plantarum</italic> 299v (LP299N&#x02122;)</td><td align="center">0/42</td><td align="center">1 x 10<sup>10</sup></td><td align="left">Not pregnant (reproductive-age women)</td><td align="center">4 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">The absorption of iron was significantly higher in the probiotic group.</td><td align="left">Hoppe et al.,<sup><xref rid="cit0037" ref-type="bibr">37</xref></sup></td></tr><tr><td align="left">Vitamin D and <italic toggle="yes">L. acidophilus, B. bifidum, L. reuteri</italic>, and <italic toggle="yes">L. fermentum</italic></td><td align="center">28/29</td><td align="center">8 &#x000d7; 10<sup>9</sup></td><td align="left">Late 2nd&#x02013;early 3rd trimester</td><td align="center">6 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Vitamin D and Probiotic group showed significantly reduced, fasting plasma glucose, serum insulin levels, and homeostasis model of assessment-insulin resistance, and significantly increased the quantitative insulin sensitivity check index. Probiotic group also showed significantly reduced triglycerides, HDL-/total cholesterol ratio, high sensitivity C-reactive protein, and malondialdehyde, also, an increase of HDL-cholesterol, and total antioxidant, when compared to placebo.</td><td align="left">Jamilian et al.,<sup><xref rid="cit0038" ref-type="bibr">38</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (V&#x000ae;) and <italic toggle="yes">B. animalis</italic> subsp <italic toggle="yes">lactis</italic> (BB-12&#x000ae;)</td><td align="center">20/10</td><td align="center">1 x 10<sup>9</sup></td><td align="left">From 1st trimester (~13.8&#x000a0;weeks)</td><td align="center">NA</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">The major differences in placental fatty acids were attributable to a higher concentration of omega-3 fatty acids in both intervention arms than in controls. Probiotic and diet group had higher concentrations of linoleic and dihomo-&#x003b3;-linolenic acids compared with dietary counselling with placebo or controls.</td><td align="left">Kaplas et al.,<sup><xref rid="cit0039" ref-type="bibr">39</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. plantarum</italic> 299v (LP299V&#x000ae;)</td><td align="center">6/7</td><td align="center">1 x 10<sup>10</sup></td><td align="left">2nd trimester</td><td align="center">17.5 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">A slower decline in maternal haematological and iron parameters across pregnancy was observed in the probiotic group compared to placebo.</td><td align="left">OjiNjideka Hemphill et al.,<sup><xref rid="cit0040" ref-type="bibr">40</xref></sup></td></tr><tr><td align="left"><bold>GDM</bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left"><italic toggle="yes">L. salivarius</italic> (UCC118)</td><td align="center">75/74</td><td align="center">1 x 10<sup>9</sup></td><td align="left">Mid-late pregnancy</td><td align="center">8 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">No differences between the probiotic and placebo groups in postintervention fasting glucose. Among 100 women managed with diet and exercise alone, fasting plasma glucose decreased significantly within both the probiotic and placebo groups, but the levels between groups did not differ.</td><td align="left">Lindsay et al.,<sup><xref rid="cit0041" ref-type="bibr">41</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (V&#x000ae;) and <italic toggle="yes">B. animalis</italic> subsp <italic toggle="yes">lactis</italic> (BB-12&#x000ae;)</td><td align="center">85/85</td><td align="center">1 x 10<sup>10</sup></td><td align="left">1st trimester onward</td><td align="center">17 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">The risk of GDM was significantly reduced in the diet/probiotics group when compared to the control group.</td><td align="left">Luoto et al.,<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (HN001) and <italic toggle="yes">B. animalis subsp. lactis</italic> (420), taken with fish oil.</td><td align="center">110/110</td><td align="center">1 x 10<sup>10</sup></td><td align="left">2nd trimester</td><td align="center">26 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">No significant difference in the incidence of GDM between the intervention groups.</td><td align="left">Pellonper&#x000e4; et al.,<sup><xref rid="cit0043" ref-type="bibr">43</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (GG&#x000ae;) and <italic toggle="yes">B. animalis</italic> subsp <italic toggle="yes">lactis</italic> (BB-12&#x000ae;), and 2g Myoinositol</td><td align="center">98/48</td><td align="center">5 x 10<sup>8</sup></td><td align="left">Early-mid pregnancy</td><td align="center">15 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Significant decrease in GDM incidence in the probiotic group.</td><td align="left">Reyes-Mu&#x000f1;oz et al.,<sup><xref rid="cit0044" ref-type="bibr">44</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. acidophilus</italic> (LA1), <italic toggle="yes">B. longum</italic> (sp54 cs), and <italic toggle="yes">B. bifidum</italic> (sp9 cs)</td><td align="center">271/271</td><td align="center">&#x0003e;7.5&#x000d7;10<sup>9</sup><break/>&#x0003e; 1.5&#x000d7;10<sup>9</sup><break/>&#x0003e; 6&#x000d7;10<sup>9</sup></td><td align="left">2nd trimester</td><td align="center">14 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">There was no significant difference between the intervention and the control group regarding FBG, OGTT-1h and OGTT-2h. The incidence of GDM in the intervention group was 41.9% which was not significantly different from the control group (40.2%).</td><td align="left">Shahriari et al.,<sup><xref rid="cit0045" ref-type="bibr">45</xref></sup></td></tr><tr><td align="left"><bold>Mental Health</bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left"><italic toggle="yes">Bifidobacterium bifidum</italic> (W23), <italic toggle="yes">Bifidobacterium lactis</italic> (W51), <italic toggle="yes">Bifidobacterium lactis</italic> (W52), <italic toggle="yes">Lactobacillus acidophilus</italic> (W37), <italic toggle="yes">Lactobacillus brevis</italic> (W63), <italic toggle="yes">Lactobacillus casei</italic> (W56), <italic toggle="yes">Lactobacillus salivarius</italic> (W24), <italic toggle="yes">Lactococcus&#x02028;lactis</italic> (W19) and <italic toggle="yes">Lactococcus lactis</italic> (W58)</td><td align="center">20/20</td><td align="center">5 x 10<sup>9</sup></td><td align="left">Late 2nd to 3rd</td><td align="center">10 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Overall, there were no significant differences between groups, except for lower depressive symptoms in the probiotic group and reduced depression-related cognitive reactivity to sad mood (LEIDS-R) in the placebo group.</td><td align="left">Browne et al.,<sup><xref rid="cit0046" ref-type="bibr">46</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (V&#x000ae;) and <italic toggle="yes">B. animalis subsp lactis</italic> (BB-12&#x000ae;)</td><td align="center">76/88</td><td align="center">6.5 x 10<sup>9</sup></td><td align="left">2nd trimester</td><td align="center">20 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">No significant difference between groups.</td><td align="left">Dawe et al.,<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (HN001) and <italic toggle="yes">B. animalis</italic> subssp. <italic toggle="yes">lactis</italic> (420)</td><td align="center">137/127</td><td align="center">1 x 10<sup>10</sup></td><td align="left">Early pregnancy</td><td align="center">10 mo</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Higher depressive symptoms during pregnancy and at 12 months postpartum compared to the placebo group.</td><td align="left">Hulkkonen et al.,<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup>;</td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (HN001)</td><td align="center">211/212</td><td align="center">6 x 10<sup>9</sup></td><td align="left">2nd trimester to postpartum</td><td align="center">15 wk</td><td align="left">Oral</td><td align="center">NA</td><td align="center">NA</td><td align="left">Mothers in the probiotic treatment group reported significantly lower scores for depression and anxiety postpartum compared to the placebo group.</td><td align="left">Slykerman et al.,<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup></td></tr><tr><td align="left"><bold>Preterm Birth</bold></td><td align="center">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="center">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr><tr><td align="left"><italic toggle="yes">L. crispatus</italic> (CTV-05)</td><td align="center">2190/61</td><td align="center">2 x 10<sup>9</sup></td><td align="left">2nd trimester</td><td align="center">6 wk</td><td align="left">Vaginal</td><td align="center">NA</td><td align="center">NA</td><td align="left">The rate of early PTB &#x0003c;34&#x000a0;weeks in the probiotic group was 3.3% compared to 7% in a historical cohort of women at similar background PTB risk with no probiotic administration.</td><td align="left">Bayar et al.,<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup>;</td></tr><tr><td align="left"><italic toggle="yes">L. casei rhamnosus</italic> (Lcr regenerans)</td><td align="center">79/59</td><td align="center">1 x 10<sup>7</sup></td><td align="left">1st trimester</td><td align="center">8 d</td><td align="left">Vaginal</td><td align="left">Vaginal (Nugent score)</td><td align="left">&#x02193; Nugent score only in women without baseline <italic toggle="yes">lactobacilli</italic></td><td align="left">No significant differences in preterm birth rates between groups.</td><td align="left">Petricevic et al.,<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup></td></tr><tr><td align="left"><italic toggle="yes">L. rhamnosus</italic> (GR-1&#x000ae;) and <italic toggle="yes">L. reuteri</italic> (RC-14&#x000ae;)</td><td align="center">32/34</td><td align="center">2.5 &#x000d7; 10<sup>9</sup> (each strain)</td><td align="left">1st to 3rd trimester</td><td align="center">12 wk</td><td align="left">Oral</td><td align="left">Vaginal (Nugent, sequencing)</td><td align="left">No change in diversity or Nugent score; <italic toggle="yes">Lactobacillus iners</italic>, <italic toggle="yes">G. vaginalis</italic> dominant.</td><td align="left">No significant differences in premature birth.</td><td align="left">Yang et al.,<sup><xref rid="cit0052" ref-type="bibr">52</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p>CFU &#x02013; Colony Forming Units; adm &#x02013; Administration; NA &#x02013; Not Available; RCT &#x02013; Randomised Controlled Trial; GBS &#x02013; Group B <italic toggle="yes">Streptococcus</italic>; Nugent score &#x02013; Nugent score; LEIDS-R &#x02013; Leiden Index of Depression Sensitivity &#x02013; Revised; PTB &#x02013; Preterm Birth; FBG &#x02013; Fasting Blood Glucose; OGTT-1h/OGTT-2h &#x02013; Oral Glucose Tolerance Test at 1 hour/2&#x000a0;hours; GDM &#x02013; Gestational Diabetes Mellitus; AST &#x02013; Aspartate Aminotransferase; ALT &#x02013; Alanine Aminotransferase; VLDL &#x02013; Very Low-Density Lipoprotein; HDL &#x02013; High-Density Lipoprotein.</p></fn></table-wrap-foot></table-wrap></p><p>Studies with oral supplementation of <italic toggle="yes">L. rhamnosus</italic> (GR-1&#x000ae;) and <italic toggle="yes">L. reuteri</italic> (RC-14&#x000ae;) were randomized placebo controlled clinical trials with more than 450 women with primary and secondary outcomes associated with vaginal microbiota shifts including GBS colonization, pruritus, vaginal discharge, and pregnancy outcome including preterm delivery.<sup><xref rid="cit0026" ref-type="bibr">26&#x02013;29</xref>,<xref rid="cit0053" ref-type="bibr">53</xref></sup></p><p>Although the probiotic strains used in these studies were obtained from the same source, the probiotic dose and intervention period differed. Gille et al.<sup><xref rid="cit0026" ref-type="bibr">26</xref></sup> reported a non-significant decrease, rather than an increase, in the proportion of normal vaginal microbiota as measured by the Nugent score, a Gram staining scoring system that assesses the balance of <italic toggle="yes">Lactobacillus</italic>, <italic toggle="yes">Gardnerella</italic>, and <italic toggle="yes">Mobiluncus</italic> to classify vaginal microbes. Similar findings were also reported by Farr et al. (2019) when studying dietary supplementation with four viable strains; 2&#x02009;&#x000d7;&#x02009;10<sup>8</sup>
<italic toggle="yes">L. jensenii</italic> LBV 116&#x02122; 10<sup>11</sup> colony forming units (CFU)/g (DSM 22,566); 1&#x02009;&#x000d7;&#x02009;10<sup>8</sup>
<italic toggle="yes">L. crispatus</italic> LBV88&#x02122; 10<sup>11</sup> CFU/g (DSM 22,566); 1&#x02009;&#x000d7;&#x02009;10<sup>8</sup>
<italic toggle="yes">L. rhamnosus</italic> (LBV 96&#x02122;) 10<sup>11</sup> CFU/g (DSM 22,560); 3&#x02009;&#x000d7;&#x02009;10<sup>8</sup>
<italic toggle="yes">L</italic>. (LBV 150N&#x02122;) 10<sup>11</sup> CFU/g (DSM 22,583).<sup>26</sup></p></sec><sec disp-level="3" id="s0003-s2001-s3002"><label>3.1.2.</label><title>Intervention duration and dose variability</title><p>Ho et al. (2016)<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup> demonstrated that the probiotic intervention could reduce vaginal and rectal GBS colonization rates in pregnant women and proposed that oral probiotics should be administrated early in pregnancy to reduce GBS colonization at 35&#x02013;37&#x02009;weeks of gestation. Olsen et al.<sup><xref rid="cit0028" ref-type="bibr">28</xref></sup> reported that this probiotic intervention had no significant impact on vaginal GBS rates; however, they demonstrated a significant increase in vaginal commensals in the probiotic group. Additionally, a prospective study with oral supplementation of <italic toggle="yes">L. salivarius</italic> (CECT 9145) in a total of 57 pregnant women (39 rectal and vaginal <italic toggle="yes">S. agalactiae</italic>/GBS-positive women; 18 rectal and vaginal GBS-negative women) was conducted to determine the impact of the intervention on GBS eradication.<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup> Interestingly, the isolation and identification of the candidate probiotic strain for this human intervention study were based on target mechanisms of action, namely anti-microbial activities against GBS (<xref rid="f0002" ref-type="fig">Figure 2</xref>).
<fig position="float" id="f0002" fig-type="figure"><label>Figure 2.</label><caption><p>Probiotic supplementation during pregnancy and its mechanisms of impact on maternal health, including effects on mood, nutrient status, preterm birth, Group B <italic toggle="yes">Streptococcus</italic> (GBS) infection, and constipation. Figure created with BioRender. Flores, V.E. (2025) <ext-link xlink:href="https://BioRender.com/p25dwhp" ext-link-type="uri">https://BioRender.com/p25dwhp</ext-link>.</p></caption><alternatives><graphic xlink:href="KGMI_A_2501186_F0002_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="KGMI_A_2501186_F0002_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p></sec><sec disp-level="3" id="s0003-s2001-s3003"><label>3.1.3.</label><title>Limitations of GBS probiotic intervention trials</title><p>Although the perspective study had a limited number of participants, it was successful in demonstrating a significant decrease in GBS colonization during pregnancy. Key limitations include the short and variable durations of probiotic exposure, which ranged from 14&#x02009;d<sup><xref rid="cit0025" ref-type="bibr">25</xref></sup> to 3&#x02009;weeks,<sup><xref rid="cit0027" ref-type="bibr">27</xref>,<xref rid="cit0028" ref-type="bibr">28</xref></sup> while others extended to 8<sup><xref rid="cit0026" ref-type="bibr">26</xref>,<xref rid="cit0027" ref-type="bibr">27</xref></sup> and 12&#x02009;weeks<sup><xref rid="cit0029" ref-type="bibr">29</xref></sup> cross studies. Only three studies were identified as replicates in terms of probiotic strain and dosage, all of which focused on GBS as an outcome. These studies<sup><xref rid="cit0026" ref-type="bibr">26&#x02013;28</xref></sup> investigated <italic toggle="yes">L. rhamnosus</italic> (GR-1&#x000ae;) and <italic toggle="yes">L. reuteri</italic> (RC-14&#x000ae;), administered at 10<sup><xref rid="cit0008" ref-type="bibr">8</xref></sup> CFU/g.</p><p>In conclusion, current evidence suggests a potential for <italic toggle="yes">Lactobacillus</italic> probiotic interventions to reduce the risk for maternal GBS infection, when taking into account antimicrobial activity against GBS and when applied in the most effective time window during gestation, specifically, a 3-week treatment in the second trimester.<sup><xref rid="cit0027" ref-type="bibr">27</xref></sup></p></sec></sec><sec disp-level="2" id="s0003-s2002"><label>3.2.</label><title>Maternal constipation</title><sec disp-level="3" id="s0003-s2002-s3001"><label>3.2.1.</label><title>Small-scale study example</title><p>A four-week pilot study assessing the administration of a multi-strain formulation containing <italic toggle="yes">Bifidobacterium bifidum</italic> (W23), <italic toggle="yes">Bifidobacterium animalis</italic> subsp. <italic toggle="yes">lactis</italic> (W52), <italic toggle="yes">Bifidobacterium longum</italic> (W108), <italic toggle="yes">Lacticaseibacillus casei</italic> (W79), <italic toggle="yes">Lactiplantibacillus plantarum</italic> (W62) and <italic toggle="yes">L. rhamnosus</italic> (W71) during pregnancy showed a significant increase in bowel movement frequency in 20 constipated women. There was also a significant decrease in the presence of sensation of incomplete evacuation, sensation of anorectal obstruction, straining during defecation, abdominal pain, and reflux episodes, but no effect on hard stools and manual maneuvers. No side effects were reported.<sup><xref rid="cit0030" ref-type="bibr">30</xref></sup></p></sec><sec disp-level="3" id="s0003-s2002-s3002"><label>3.2.2.</label><title>Yogurt-based intervention study</title><p>In addition, in a randomized controlled trial (RCT), a treatment group of pregnant women received 300&#x02009;g of yogurt enriched with <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic>, (BB-12&#x000ae;) and <italic toggle="yes">Lactobacillus acidophilus</italic> (LA-5&#x000ae;) 4.8&#x02009;&#x000d7;&#x02009;10<sup>10</sup> CFU, while the control group consumed conventional yoghurt without added probiotics (<italic toggle="yes">n</italic>&#x02009;=&#x02009;30) for 4&#x02009;weeks. Both probiotic and conventional yogurts contained <italic toggle="yes">Lactobacillus bulgaricus</italic> and <italic toggle="yes">Streptococcus thermophilus</italic>. In both groups, a significant increase in frequency of defecation and amount of stool was observed. Symptoms such as straining and sensation of anorectal obstruction decreased, whereas the need for manipulation to facilitate defecation increased significantly in both groups. No significant effect on the sensation of incomplete evacuation after defecation was observed.<sup><xref rid="cit0031" ref-type="bibr">31</xref></sup></p></sec><sec disp-level="3" id="s0003-s2002-s3003"><label>3.2.3.</label><title>Limitations of current studies</title><p>None of these studies measured mechanistic parameters. Furthermore, generalizability to the broader population remains limited. For example, one study on constipation included only cases (i.e. no control group),<sup><xref rid="cit0030" ref-type="bibr">30</xref></sup> precluding between-group comparisons, and had a duration of just 4 weeks.<sup><xref rid="cit0030" ref-type="bibr">30</xref></sup> In contrast, the study with the largest sample size, 152 participants in both the treatment and placebo groups,<sup><xref rid="cit0032" ref-type="bibr">32</xref></sup> also had a long treatment duration (26&#x02009;weeks). However, despite its scale, it failed to identify significant differences or changes between groups.</p><p>In conclusion, although the effects of probiotic interventions on maternal constipation have been described, the overall efficacy and benefits are inconsistent.</p></sec></sec><sec disp-level="2" id="s0003-s2003"><label>3.3.</label><title>Maternal nutrient status</title><sec disp-level="3" id="s0003-s2003-s3001"><label>3.3.1.</label><title>Effects of specific probiotic strains</title><p>Several clinical trials demonstrated significant effects of various probiotic supplements on maternal nutrient status, including <italic toggle="yes">L. plantarum</italic> 299&#x02009;v (LP299V&#x000ae;), multi-strain probiotic capsules containing <italic toggle="yes">L. acidophilus</italic>, <italic toggle="yes">L. casei</italic>, <italic toggle="yes">B. bifidum</italic>, and <italic toggle="yes">Limosilactobacillus fermentum</italic> (2&#x02009;&#x000d7;&#x02009;10<sup>9</sup> CFU/g each),<sup><xref rid="cit0054" ref-type="bibr">54</xref></sup> capsules containing <italic toggle="yes">L</italic>. <italic toggle="yes">rhamnosus</italic> (GG&#x000ae;) (ATCC 53,103; Valio, Helsinki, Finland) and <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic>, (BB-12&#x000ae;) (Chr. Hansen, H&#x000f8;rsholm, Denmark) 10<sup><xref rid="cit0009" ref-type="bibr">9</xref></sup> CFU/day, and probiotic-enriched foods, with no adverse effects.<sup><xref rid="cit0039" ref-type="bibr">39</xref></sup></p></sec><sec disp-level="3" id="s0003-s2003-s3002"><label>3.3.2.</label><title>Iron absorption and anemia</title><p>LP299V&#x000ae; administration was shown to positively impact dietary iron bioavailability and reduce the prevalence of iron deficiency anemia early in pregnancy.<sup><xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0036" ref-type="bibr">36</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0040" ref-type="bibr">40</xref></sup> Mechanistic insights suggest that LP299V&#x000ae; increases ferric iron (Fe<sup>3+</sup>) levels in digested meals, potentially by affecting ferric reductase activity and phytate degradation (<xref rid="f0002" ref-type="fig">Figure 2</xref>). Only one trial reported adverse effects, which may have been due to the combination of iron supplementation and LP299V.<sup><xref rid="cit0034" ref-type="bibr">34</xref></sup></p></sec><sec disp-level="3" id="s0003-s2003-s3003"><label>3.3.3.</label><title>Lipid metabolism and oxidative stress</title><p>In addition, two probiotic intervention studies with multi-strain probiotic supplementation, one containing <italic toggle="yes">L. acidophilus</italic>, <italic toggle="yes">L. casei</italic>, <italic toggle="yes">B. bifidum</italic>, and <italic toggle="yes">Limosilactobacillus fermentum</italic> (2&#x02009;&#x000d7;&#x02009;10<sup>9</sup> CFU/g each) for 6&#x02009;weeks in a 24/24 placebo/treatment group, and the other with <italic toggle="yes">L. rhamnosus</italic> (GR-1&#x000ae;), and <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic> (BB-12&#x000ae;) at 10<sup>9</sup> CFU/g in a 20/10 placebo/treatment during pregnancy, significantly improved lipid profiles and reduced oxidative stress.<sup><xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0039" ref-type="bibr">39</xref></sup> The suggested underlying mechanisms of action include regulation of peroxisome proliferator activated receptor gamma (PPAR-&#x003b3;) gene expression, modulation of toll-like receptor-mitogen-activated protein kinase-PPAR-&#x003b3; signaling pathways, and increased production of SCFAs, which affect various metabolic pathways (<xref rid="f0002" ref-type="fig">Figure 2</xref>).</p><p>Further, there may be effects on the placenta: multi-strain probiotics may modify placental phospholipid fatty acids and influence systemic effects through similar signaling pathways as fatty acids, including soluble cluster of differentiation 14 (CD14) and proinflammatory cytokines.<sup><xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0039" ref-type="bibr">39</xref></sup></p></sec><sec disp-level="3" id="s0003-s2003-s3004"><label>3.3.4.</label><title>Combined micronutrient and probiotic supplementation</title><p>Additionally, encapsulated micronutrients and probiotic supplementation were included in a clinical trial with pregnant women receiving Vitamin D and probiotic co-supplementation containing 8&#x02009;&#x000d7;&#x02009;10<sup>9</sup> CFU/day of <italic toggle="yes">L. acidophilus, B. bifidum, L. reuteri</italic>, and <italic toggle="yes">L. fermentum</italic>, strains not indicated. Vitamin D and probiotic co-supplementation significantly reduced triglyceride levels compared to the placebo, and a similar but smaller reduction in triglycerides was observed in the probiotic-only group. This might be mediated by modulation of gene expression related to lipid metabolism, suppression of toll-like receptor signaling pathways, and increased production of SCFAs.<sup><xref rid="cit0038" ref-type="bibr">38</xref></sup></p></sec><sec disp-level="3" id="s0003-s2003-s3005"><label>3.3.5.</label><title>Calcium absorption</title><p>Furthermore, consumption of a probiotic yogurt enriched with <italic toggle="yes">L. acidophilus</italic>, (LA-5&#x000ae;) and <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic> (BB-12&#x000ae;) 1&#x02009;&#x000d7;&#x02009;10<sup>7</sup> CFU/ml (a total of 200&#x02009;&#x000d7;&#x02009;10<sup>7</sup> CFU/day) by pregnant women helped to maintain serum calcium levels compared to conventional yogurt, possibly by enhancing calcium solubility and increasing calcium absorption.<sup><xref rid="cit0033" ref-type="bibr">33</xref></sup></p></sec><sec disp-level="3" id="s0003-s2003-s3006"><label>3.3.6.</label><title>Study design limitations and overall findings</title><p>It is important to note that these are unique studies, so direct comparison between them is not possible. While some studies included larger sample sizes, for example, 110 and 118 participants in the placebo and intervention groups, respectively, with an extended exposure period of 25&#x02009;weeks,<sup><xref rid="cit0034" ref-type="bibr">34</xref></sup> others involved notably smaller cohorts, shorter treatment durations, and differed in dosages and probiotic strains.</p><p>Overall, these findings suggest direct improvement of nutrient absorption and indirect modulation of the physiological mechanisms contributing to increased nutrient absorption and utilization by probiotics during pregnancy.</p></sec></sec><sec disp-level="2" id="s0003-s2004"><label>3.4.</label><title>Gestational diabetes mellitus</title><sec disp-level="3" id="s0003-s2004-s3001"><label>3.4.1.</label><title>Early clinical trials</title><p>To date, seven clinical trials examining the effects of probiotics on GDM have been conducted. One of the first, a double-blind RCT of pregnant women with impaired glucose tolerance or GDM, was published over a decade ago and revealed that daily consumption of <italic toggle="yes">L</italic>. <italic toggle="yes">salivarius</italic> (UCC118) at a target dose of 10<sup>9</sup> CFU did not reduce fasting blood glucose levels nor change metabolic parameters and pregnancy outcomes. Importantly, in both arms (placebo, probiotic), pre-intervention blood glucose was significantly higher than post-intervention showing that the mandated lifestyle guidelines for diet and exercise are effective for managing GDM, and probiotic treatment does not mediate or amplify these effects.<sup><xref rid="cit0041" ref-type="bibr">41</xref></sup> In a second historic study from 2010, intensive dietary counseling provided by a nutritionist, combined with a probiotic supplement, significantly decreased the frequency of GDM compared to a control group without dietary intervention. However, no direct comparison was made with the participant group that received dietary intervention and a placebo.<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup></p></sec><sec disp-level="3" id="s0003-s2004-s3002"><label>3.4.2.</label><title>Recent RCTs with null findings</title><p>More recent studies present similar findings. Two double-blind RCTs in overweight and obese pregnant women supplemented with <italic toggle="yes">L. rhamnosus</italic> (GG&#x000ae;) and <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic>, (BB-12&#x000ae;) at a dose of&#x02009;&#x0003e;10<sup>9</sup> CFU showed no effect on GDM or other maternal and neonate markers.<sup><xref rid="cit0043" ref-type="bibr">43</xref>,<xref rid="cit0045" ref-type="bibr">45</xref></sup> A double-blind RCT with <italic toggle="yes">L. rhamnosus</italic> (HN001) and <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic> (420) (10<sup>10</sup> CFU each), taken with or without fish oil, did not show any effects compared to placebo,<sup><xref rid="cit0043" ref-type="bibr">43</xref></sup> and also a fourth study, with <italic toggle="yes">L</italic>. <italic toggle="yes">acidophilus</italic> (LA1) (&#x0003e;7.5&#x02009;&#x000d7;&#x02009;10<sup>9</sup> CFU), <italic toggle="yes">B. longum</italic> (sp54 cs) (&#x0003e;1.5&#x02009;&#x000d7;&#x02009;10<sup>9</sup> CFU), and <italic toggle="yes">B. bifidum</italic> (sp9 cs) (&#x0003e;6&#x02009;&#x000d7;&#x02009;10<sup>9</sup> CFU) did not demonstrate an effect.<sup><xref rid="cit0045" ref-type="bibr">45</xref></sup> A final study examining supplementation of <italic toggle="yes">L. rhamnosus</italic> (HN001) (6&#x02009;&#x000d7;&#x02009;10<sup>9</sup> CFU) in pregnant women with personal or partner history of atopic disease found a positive effect on GDM in women &#x0003e;35&#x02009;yrs and those with a history of GDM.</p></sec><sec disp-level="3" id="s0003-s2004-s3003"><label>3.4.3.</label><title>Current consensus and mechanistic considerations</title><p>Taken together, the utility of probiotics seems limited with regard to reducing the risk of GDM, and the current best practice of diet control and exercise offers more reliable, population-wide treatment outcomes. It is important to note that some reviews and meta-analyses suggest positive effects of probiotics in GDM,<sup><xref rid="cit0055" ref-type="bibr">55&#x02013;57</xref></sup> but referenced studies have large variability in methods, metrics, and often have confounders (e.g. co-supplement of myo-inositol).<sup><xref rid="cit0044" ref-type="bibr">44</xref></sup> Given the strong effect size of lifestyle changes in multiple studies and the mounting evidence of the dearth of probiotics&#x02019; effects in this disease, coupled with large interstudy variability, a better understanding of how gut microbiota is involved in mediating dietary management in GDM outcomes might increase the chances of targeted probiotic interventions to modulate microbiota composition and thereby potentially lead to more pronounced outcomes in the future.<sup><xref rid="cit0058" ref-type="bibr">58</xref></sup></p></sec><sec disp-level="3" id="s0003-s2004-s3004"><label>3.4.4.</label><title>Sample size, duration, and limitations</title><p>It must be highlighted that while some studies had robust sample sizes and extended intervention durations, such as 271/271 placebo/control participants over 14&#x02009;weeks<sup><xref rid="cit0042" ref-type="bibr">42</xref></sup> and 110 participants over 26&#x02009;weeks,<sup><xref rid="cit0045" ref-type="bibr">45</xref></sup> no significant differences in GDM incidence were observed. These findings emphasize that even well-powered studies with longer exposures may yield limited clinical effects.</p></sec></sec><sec disp-level="2" id="s0003-s2005"><label>3.5.</label><title>Mental health</title><sec disp-level="3" id="s0003-s2005-s3001"><label>3.5.1.</label><title>Overview of available evidence</title><p>Limited clinical data is available on the use of probiotics during pregnancy and the impact on women&#x02019;s mental health. In the few published clinical trials, there have been inconsistent outcomes potentially resulting from the use of different probiotic strains, limited samples sizes, methodological differences, and differences in the timing and length of probiotic intervention (<xref rid="t0001" ref-type="table">Table 1</xref>).<sup><xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0059" ref-type="bibr">59</xref>,<xref rid="cit0060" ref-type="bibr">60</xref></sup></p></sec><sec disp-level="3" id="s0003-s2005-s3002"><label>3.5.2.</label><title>Pilot and small-scale studies</title><p>Browne et al. (2021)<sup><xref rid="cit0046" ref-type="bibr">46</xref></sup> executed a pilot RCT with 40 pregnant women and reported no significant improvement in maternal mood or psychological distress in the probiotic group supplemented with <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic> (BB-12&#x000ae;), and <italic toggle="yes">L</italic>. <italic toggle="yes">rhamnosus</italic> (GG&#x000ae;), compared to the control. This study was limited by the study design, particularly the sample size.</p></sec><sec disp-level="3" id="s0003-s2005-s3003"><label>3.5.3.</label><title>Moderate- to large-scale trials</title><p>Hulkkonen et al.<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup> demonstrated a modest impact on depressive symptoms in a RCT with 430 overweight pregnant women with an intervention of <italic toggle="yes">L</italic>. <italic toggle="yes">rhamnosus</italic> (HN001), <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic> 420, and fish oil; however, the most successful clinical study was reported by Slykerman et al.<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup> Indeed, in a double-blind, multi-center RCT including 433 women, supplementations with <italic toggle="yes">L</italic>. <italic toggle="yes">rhamnosus</italic> (HN001) during and after pregnancy resulted in significantly lower prevalence of symptoms of depression and anxiety postpartum. A strength of this study was the sample size, and researchers suggested potential mechanisms of action are associated with gamma-aminobutyric acid (GABA) receptor expression, thereby alleviating anxiety-associated behavior (<xref rid="f0002" ref-type="fig">Figure 2</xref>).</p></sec><sec disp-level="3" id="s0003-s2005-s3004"><label>3.5.4.</label><title>Meta-analyses and conflicting outcomes</title><p>In line with this, a recent systematic review and meta-analysis<sup><xref rid="cit0060" ref-type="bibr">60</xref></sup> including 16 trials (&#x0003e;946 pregnant women) showed that probiotic supplementation reduced anxiety in pregnancy (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.04) but had no effects on depression (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.20). Nonetheless, another systematic review,<sup><xref rid="cit0059" ref-type="bibr">59</xref></sup> including three RCTs with low risk of bias (over 713 participants), as reported using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework, reported no impact of probiotics on &#x0201c;global&#x0201d; mental health or depression scores. However, an association between probiotic supplementation and reduced anxiety symptoms was observed. More specifically, Dawe et al. (2020) randomized 230 pregnant women with obesity (BMI &#x02265; 30.0&#x02009;kg/m2) into study two arms: 1) placebo and 2) probiotic combination of <italic toggle="yes">B. animalis</italic> subsp. <italic toggle="yes">lactis</italic> (BB-12&#x000ae;) and <italic toggle="yes">L</italic>. <italic toggle="yes">rhamnosus</italic> (GG&#x000ae;). Depression, anxiety, and functional health and well-being were assessed at baseline in the first (12&#x02009;&#x02212;&#x02009;17&#x02009;weeks) and third (36&#x02009;weeks of pregnancy) trimesters. Results showed that probiotics did not modulate or improve mental health outcomes.<sup><xref rid="cit0047" ref-type="bibr">47</xref></sup></p></sec><sec disp-level="3" id="s0003-s2005-s3005"><label>3.5.5.</label><title>Summary of study design limitations</title><p>It must be highlighted that mental health studies varied considerably in sample size, dosage, supplemented strain, and duration, affecting comparability. While some trials involved small cohorts and shorter interventions, such as 20 participants over 10&#x02009;weeks,<sup><xref rid="cit0046" ref-type="bibr">46</xref></sup> others were more robust, including up to 423 participants over 15&#x02009;weeks<sup><xref rid="cit0049" ref-type="bibr">49</xref></sup> or even 10&#x02009;months.<sup><xref rid="cit0048" ref-type="bibr">48</xref></sup> Despite these strengths, results were inconsistent, with some studies showing improvements in depression or anxiety, while others reported no significant effects.</p></sec></sec><sec disp-level="2" id="s0003-s2006"><label>3.6.</label><title>Preterm birth</title><sec disp-level="3" id="s0003-s2006-s3001"><label>3.6.1.</label><title>Overview of clinical trials</title><p>Multiple clinical studies have been performed with probiotic intervention to modulate vaginal microbiota and related pregnancy outcomes. The vaginally applied probiotic <italic toggle="yes">L</italic>. <italic toggle="yes">crispatus</italic> (CTV-05) was shown to be safe and well accepted and tolerated in pregnant women at high risk for PTB.<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup> An overall systematic review and meta-analysis assessing pregnancy outcomes in women taking pro- and prebiotics,<sup><xref rid="cit0061" ref-type="bibr">61</xref></sup> including five studies on probiotics in the context of very PTB (&#x0003c;34&#x02009;weeks of gestation) and 11 studies on probiotics and PTB (&#x0003c;37&#x02009;weeks of gestation), concluded that there was no evidence for effects on the risk of PTB or other adverse pregnancy outcomes.</p></sec><sec disp-level="3" id="s0003-s2006-s3002"><label>3.6.2.</label><title>Meta-analysis limitations and interpretation</title><p>One limitation of that analysis<sup><xref rid="cit0061" ref-type="bibr">61</xref></sup> though was that only one of the included studies truly targeted the prevention of PTB, whereas most others had different primary endpoints and only reported PTB as a secondary measure. The timing and duration of the probiotic interventions also varied among studies, making direct comparison difficult. Although some promising data suggest potential beneficial effects of probiotic supplementation during pregnancy in reducing the risk of PTB, further studies are needed to confirm these findings.</p></sec><sec disp-level="3" id="s0003-s2006-s3003"><label>3.6.3.</label><title>Clinical findings: oral vs. vaginal probiotic administration</title><p>Oral supplementation of <italic toggle="yes">L</italic>. <italic toggle="yes">rhamnosus</italic> (GR-1&#x000ae;) and <italic toggle="yes">L</italic>. <italic toggle="yes">reuteri</italic> (RC-14&#x000ae;) over 12&#x02009;weeks in pregnant women resulted in slight differences in interleukin-4 and interleukin-10 production compared to placebo supplementation at 28&#x02009;weeks of gestation.<sup><xref rid="cit0052" ref-type="bibr">52</xref></sup> However, these differences were not significant at 35&#x02009;weeks, and there were no significant changes in vaginal microbiota either.<sup><xref rid="cit0032" ref-type="bibr">32</xref></sup> Therefore, oral supplementation might have more indirect effects compared to vaginal probiotic administration. Importantly, pregnant women with vaginal microbiota shifts and low abundance of lactobacilli might particularly benefit from a probiotic intervention. A small study showed that gestational age and neonatal birth weight were significantly higher in a subgroup of women lacking lactobacilli in the vaginal microbiota who received vaginal <italic toggle="yes">L</italic>. <italic toggle="yes">rhamnosus</italic> (Lcr regenerans) supplementation for 8&#x02009;d, although there was no difference in the PTB rate.<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup></p></sec><sec disp-level="3" id="s0003-s2006-s3004"><label>3.6.4.</label><title>Antibiotic prophylaxis</title><p>Finally, vaginal probiotics might be particularly relevant in the context of antibiotic prophylaxis. A recent systematic review and meta-analysis concluded that gestational age at delivery and infant birth weight were increased, and the rate of neonatal intensive care unit (NICU) admission was reduced after vaginal probiotics administration in combination with prophylactic antibiotics versus antibiotics alone in women with preterm premature rupture of membranes.<sup><xref rid="cit0044" ref-type="bibr">44</xref>,<xref rid="cit0062" ref-type="bibr">62</xref></sup></p></sec><sec disp-level="3" id="s0003-s2006-s3005"><label>3.6.5.</label><title>Study design and comparison limitations</title><p>It is important to acknowledge that studies assessing PTB varied significantly in probiotic dosage, sample size, target site (oral, vaginal) and intervention duration, limiting the comparability of their findings. While Bayar et al. included a large cohort of over 2,000 participants,<sup><xref rid="cit0050" ref-type="bibr">50</xref></sup> other trials involved fewer than 100 participants.<sup><xref rid="cit0051" ref-type="bibr">51</xref>,</sup> Similarly, treatment durations ranged from just 8&#x02009;d<sup><xref rid="cit0051" ref-type="bibr">51</xref></sup> to 12&#x02009;weeks. Despite these differences, most studies did not report significant effects on preterm birth, underscoring the need for more consistent methodologies and longer-term trials.</p></sec></sec><sec disp-level="2" id="s0003-s2007"><label>3.7.</label><title>Probiotic use during pregnancy: maternal and infant safety risks</title><p>Although microbial shifts have been implicated in various pregnancy complications, and specific bacterial taxa have even been identified as potential contributors,<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> clinical trials testing individual probiotic strains, combinations of strains, or especially &#x0201c;next-generation&#x0201d; probiotics in pregnant women remain extremely limited.<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup></p><p>To date, most RCTs with maternal probiotic supplementation have not been associated with adverse effects to the mother or fetus,<sup><xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0064" ref-type="bibr">64</xref></sup> and there is no evidence that probiotics cross the placental barrier. However, bacterial metabolites and cell components do reach the fetus, prompting clinicians to adopt a cautious approach to supplementation. This caution is further underscored by the potential for rare but serious side effects including sepsis, bacteremia, and allergy (typically to the vehicle)<sup><xref rid="cit0065" ref-type="bibr">65</xref></sup> along with mild but bothersome gastrointestinal symptoms including bloating, gas, and diarrhea. These risks must be weighed against the substantial evidence indicating that safety is strain-specific, only certain probiotic strains, rather than probiotics as a whole, are generally recognized as safe (&#x0201c;GRAS&#x0201d;), along with the associated benefits reviewed herein.</p><p>While concerns persist about long-term developmental effects or disturbance to natural microbiota colonization, the few meta-analyses exploring safety in neonates or infants do not support these concerns.<sup><xref rid="cit0064" ref-type="bibr">64</xref>,<xref rid="cit0066" ref-type="bibr">66</xref></sup> Similarly, the risks of probiotic supplementation during pregnancy are akin to a number of other interventions or behaviors that affect the microbiota of the mother and/or neonate, including diet, birth mode, birth location, drug and antibiotic use, and infant feeding mode. Longer-term follow-ups are crucial to better understand the implications of maternal probiotic use and to confirm their GRAS status, ultimately addressing any remaining concerns for clinicians and pregnant women alike.<sup><xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0067" ref-type="bibr">67</xref>,<xref rid="cit0068" ref-type="bibr">68</xref></sup></p><p>Therefore, while current evidence supports the safety of specific probiotic strains during pregnancy, with many classified as GRAS and not linked to adverse maternal or neonatal outcomes, caution remains warranted due to rare but serious risks such as sepsis or allergic reactions. Although one study reported no adverse effects in children followed up to 6 y after maternal probiotic use during gestation,<sup><xref rid="cit0069" ref-type="bibr">69</xref></sup> long-term developmental outcomes remain underexplored. This highlights the need for well-designed longitudinal studies and ongoing post-marketing surveillance to ensure safety across populations. Overall, the evidence supports a cautiously optimistic view of probiotic use in pregnancy, emphasizing the importance of strain-specific selection and continued monitoring.</p></sec></sec><sec disp-level="1" id="s0004"><label>4.</label><title>Perspective on the use of probiotics before and/or during pregnancy to support maternal-fetal health and prevent pregnancy complications</title><p>The maternal microbiota in the gut, the oral cavity, and the vagina undergo significant changes during pregnancy. A substantial body of scientific literature supports the maternal microbiota as a target for intervention during pregnancy to prevent pregnancy complications. Importantly, for effective probiotic interventions, the specific microbial community at the target site of action needs to be taken into account.<sup><xref rid="cit0070" ref-type="bibr">70</xref></sup> For example, evidence suggests that the maternal gut microbiota can support a healthy pregnancy when it has a high alpha diversity and is enriched in SCFA-producing bacteria such as bifidobacteria.<sup><xref rid="cit0071" ref-type="bibr">71</xref></sup> A healthy vaginal microbiota during pregnancy typically exhibits low microbial diversity with predominance of <italic toggle="yes">Lactobacillus</italic> species capable of producing lactic acid and other antimicrobial compounds.<sup><xref rid="cit0072" ref-type="bibr">72</xref></sup> Finally, beneficial features of a healthy oral microbiome during pregnancy are resistant to microbial shifts and the proliferation of opportunistic pathogens such as <italic toggle="yes">F. nucleatum</italic> and <italic toggle="yes">P. gingivalis</italic>.<sup><xref rid="cit0073" ref-type="bibr">73</xref></sup> Thus, probiotic strains with particular benefits during pregnancy should be selected based on their specific characteristics and potential to work through a defined mode of action at the target site to ultimately support a healthy pregnancy.</p><p>As reviewed here, in a few specific cases, probiotic intervention during pregnancy has been clinically proven to support maternal health and prevent pregnancy complications. However, to date, overall clinical evidence is limited and variable. This variability is due to many challenges with probiotic intervention studies such as limited knowledge on optimal probiotic strain selection criteria, intervention periods, doses, and host factor interactions (e.g. genetic) that can influence clinical outcomes.</p><p>Further complicating research on probiotics efficacy are the cohort-specific microbiota dynamics and features that can vary more geographically than between host phenotypes. Future clinical studies will benefit from clearly defined probiotic properties, or even a shift to postbiotics, to target relevant mechanisms. Strict control of variables, along with stratification of target populations, will help clarify mechanisms of action. This approach can also account for non-responders and support more meaningful clinical outcomes.</p><p>To our knowledge, the clinical efficacy of probiotics in alleviating constipation during pregnancy is under-researched, with only two relevant studies identified.<sup><xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0031" ref-type="bibr">31</xref></sup> Additionally, many interventions with probiotics supplementation during pregnancy have relatively short periods of exposure and follow-up, making it difficult to assess long-term benefits (and risks) in participants.<sup><xref rid="cit0038" ref-type="bibr">38</xref></sup> Thus, there is a need for larger, well-designed, well-controlled RCTs to accurately assess the effectiveness of specific probiotic interventions during pregnancy, including in some areas that have not been studied extensively so far, such as preeclampsia and other hypertensive disorders. Additionally, probiotics as a preventative measure rather than a reactionary one should also be considered in high-risk patients.</p></sec><sec disp-level="1" id="s0005"><label>5.</label><title>Conclusion</title><p>This review underscores the significant potential of targeting maternal microbiota with probiotics during pregnancy. While the empirical evidence shows mostly non-significant effects, the interest in this area remains high due to the critical role the microbiota plays in maternal and fetal health. The variability in study outcomes can largely be attributed to technical limitations such as small sample sizes, short follow-up periods, heterogenous target populations, and a lack of precision in probiotic strain selection or dosage tailored to specific mechanisms and sites of action. To move this field forward, future clinical studies should be conducted with optimized planning, interventions, and reporting such as:
<list list-type="order" id="list_0001"><list-item><p>Investigating the underlying biological mechanisms with a multidisciplinary approach to better understand how specific microbiota dynamics and probiotics influence pregnancy outcomes.</p></list-item><list-item><p>Clearly defining clinical outcome(s) and biological marker(s) informed by pre-clinical evidence and large-cohort meta-analyses.</p></list-item><list-item><p>Designing larger, long-term intervention clinical trials that are adequately powered to detect clinically meaningful effects.</p></list-item><list-item><p>Developing standardized protocols for probiotic interventions, such as dose and strain definition, to enable more consistent and comparable results across studies.</p></list-item><list-item><p>Systematic reporting of protocol, adverse events, and positive and negative clinical trial outcomes.</p></list-item><list-item><p>Exploring the use of not only single strain but multi-strain probiotics or synbiotics to enhance therapeutic outcomes, given their potential for synergistic effects.</p></list-item><list-item><p>Studying efficacy in diverse populations to understand if effects or absence thereof are generalizable.</p></list-item></list></p><p>Importantly, it is crucial to proceed with caution, ensuring rigorous evaluation of the safety and efficacy of probiotic products before widespread usage in pregnant populations is endorsed. Ultimately, by addressing these challenges and building on the existing knowledge base, the field can advance toward more targeted and effective probiotic interventions that are both safe and beneficial for pregnant women and their babies.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Sarah Lebeer and Yvan Vandenplas for their help with the initial vision for the project. The authors thank Maria Carmen Collado for her contributions to the discussion. The authors also thank Arthur Ouwehand, Delphine Saulnier, and Vicenta Garcia Campayo for their contributions to the review of the manuscript. This work was conducted by an expert group of ILSI Europe. This publication was coordinated by the Probiotics Task Force. Industry members of this task force are listed on the ILSI Europe website at <ext-link xlink:href="https://ilsi.eu/scientific-activities/nutrition/probiotics/" ext-link-type="uri">https://ilsi.eu/scientific-activities/nutrition/probiotics/</ext-link>. Experts are not paid for the time spent on this work; however, the non-industry members within the expert group were offered support for travel and accommodation costs from the Probiotics Task Forces to attend meetings to discuss the manuscript and a small compensatory sum (honoraria) with the option to decline.</p><p>The expert group carried out the work, i.e. collecting/analyzing data/information and writing the scientific paper separately to other activities of the task forces. The research reported is the result of a scientific evaluation in line with ILSI Europe&#x02019;s framework to provide a precompetitive setting for public&#x02013;private partnership (PPP). ILSI Europe facilitated scientific meetings and coordinated the overall project management and administrative tasks relating to the completion of this work. For further information about ILSI Europe, please email info@ilsieurope.be or call&#x02009;+&#x02009;32 2 771 00 14. The opinions expressed herein and the conclusions of this publication are those of the authors and do not necessarily represent the views of ILSI Europe nor those of its member companies.</p></ack><sec sec-type="COI-statement" disp-level="1" id="s0006"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec disp-level="1" id="s0007"><title>Author contribution</title><p>All authors contributed equally to the conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization, and writing of both the original draft and the review and editing.</p></sec><sec disp-level="1" id="s0008"><title>Abbreviations</title><p>
<def-list><def-item><term>ISAPP</term><def><p>The International Scientific Association for Probiotics and Prebiotics</p></def></def-item><def-item><term>PTB</term><def><p>Pre-term birth</p></def></def-item><def-item><term>GDM</term><def><p>Gestational diabetes mellitus</p></def></def-item><def-item><term>PE</term><def><p>Pre-eclampsia</p></def></def-item><def-item><term>GBS</term><def><p>Group B <italic toggle="yes">Streptococcus</italic></p></def></def-item><def-item><term>RCT</term><def><p>Randomised ontrolled rial</p></def></def-item><def-item><term>PPAR-&#x003b3;</term><def><p>Peroxisome proliferator ctivated receptor-gamma</p></def></def-item><def-item><term>CD14</term><def><p>Cluster of differentiation 14</p></def></def-item><def-item><term>SCFAs</term><def><p>Short hain fatty acids</p></def></def-item><def-item><term>CFU</term><def><p>Colony forming units</p></def></def-item><def-item><term>GABA</term><def><p>Gamma-aminobutyric acid</p></def></def-item></def-list></p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calatayud</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Koren</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Collado</surname>
<given-names>MC.</given-names></string-name></person-group>
<article-title>Maternal microbiome and metabolic health program microbiome development and health of the offspring</article-title>. <source>Trends Endocrinol Metab: TEM</source>. <year>2019</year>;<volume>30</volume>(<issue>10</issue>):<fpage>735</fpage>&#x02013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tem.2019.07.021</pub-id>.<pub-id pub-id-type="pmid">31493988</pub-id>
</mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koren</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Konnikova</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Brodin</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mysorekar</surname>
<given-names>IU</given-names></string-name>, <string-name><surname>Collado</surname>
<given-names>MC</given-names></string-name></person-group>. <article-title>The maternal gut microbiome in pregnancy: implications for the developing immune system</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2024</year>;<volume>21</volume>(<issue>1</issue>):<fpage>35</fpage>&#x02013;<lpage>45</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41575-023-00864-2</pub-id>.<pub-id pub-id-type="pmid">38097774</pub-id>
</mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nuriel-Ohayon</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Neuman</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Koren</surname>
<given-names>O</given-names></string-name></person-group>. <article-title>Microbial changes during pregnancy, birth, and infancy</article-title>. <source>Front Microbiol</source>. <year>2016</year>;<volume>7</volume>:<fpage>1031</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2016.01031</pub-id>.<pub-id pub-id-type="pmid">27471494</pub-id>
</mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Giannella</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Grelloni</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Quintili</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Fiorelli</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Montironi</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Alia</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Delli Carpini</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Di Giuseppe</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Vignini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ciavattini</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Microbiome changes in pregnancy disorders</article-title>. <source>Antioxidants</source>. <year>2023</year>;<volume>12</volume>(<issue>2</issue>):<fpage>463</fpage>. doi: <pub-id pub-id-type="doi">10.3390/antiox12020463</pub-id>.<pub-id pub-id-type="pmid">36830021</pub-id>
</mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Turjeman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Collado</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Koren</surname>
<given-names>O</given-names></string-name></person-group>. <article-title>The gut microbiome in pregnancy and pregnancy complications</article-title>. <source>Curr Opin Endocr Metabolic Res</source>. <year>2021</year>;<volume>18</volume>:<fpage>133</fpage>&#x02013;<lpage>138</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.coemr.2021.03.004</pub-id>.</mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hill</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Guarner</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Reid</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Gibson</surname>
<given-names>GR</given-names></string-name>, <string-name><surname>Merenstein</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Pot</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Morelli</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Canani</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Flint</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Salminen</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Expert consensus document: the international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic</article-title>. <source>Nat Rev Gastroenterol Hepatol</source>. <year>2014</year>;<volume>11</volume>(<issue>8</issue>):<fpage>506</fpage>&#x02013;<lpage>514</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrgastro.2014.66</pub-id>.<pub-id pub-id-type="pmid">24912386</pub-id>
</mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Didari</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Solki</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mozaffari</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Nikfar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Abdollahi</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>A systematic review of the safety of probiotics</article-title>. <source>Expert Opin Drug Saf</source>. <year>2014</year>;<volume>13</volume>(<issue>2</issue>):<fpage>227</fpage>&#x02013;<lpage>239</lpage>. doi: <pub-id pub-id-type="doi">10.1517/14740338.2014.872627</pub-id>.<pub-id pub-id-type="pmid">24405164</pub-id>
</mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zawistowska-Rojek</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tyski</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>Are probiotic really safe for humans?</article-title>
<source>Pol J Microbiol</source>. <year>2018</year>;<volume>67</volume>(<issue>3</issue>):<fpage>251</fpage>&#x02013;<lpage>258</lpage>. doi: <pub-id pub-id-type="doi">10.21307/pjm-2018-044</pub-id>.<pub-id pub-id-type="pmid">30451441</pub-id>
</mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McFarland</surname>
<given-names>LV</given-names></string-name>, <string-name><surname>Evans</surname>
<given-names>CT</given-names></string-name>, <string-name><surname>Goldstein</surname>
<given-names>EJC</given-names></string-name></person-group>. <article-title>Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis</article-title>. <source>Front Med (Lausanne)</source>. <year>2018</year>;<volume>5</volume>:<fpage>124</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2018.00124</pub-id>.<pub-id pub-id-type="pmid">29868585</pub-id>
</mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mazziotta</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Tognon</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Martini</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Torreggiani</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Rotondo</surname>
<given-names>JC</given-names></string-name></person-group>. <article-title>Probiotics mechanism of action on immune cells and beneficial effects on human health</article-title>. <source>Cells</source>. <year>2023</year>;<volume>12</volume>(<issue>1</issue>):<fpage>184</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells12010184</pub-id>.<pub-id pub-id-type="pmid">36611977</pub-id>
</mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McFarland</surname>
<given-names>LV</given-names></string-name>, <string-name><surname>Karakan</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Karatas</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: a systematic review and meta-analysis</article-title>. <source>EClinicalMedicine</source>. <year>2021</year>;<volume>41</volume>:<fpage>101154</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101154</pub-id>.<pub-id pub-id-type="pmid">34712929</pub-id>
</mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nuriel-Ohayon</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Neuman</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Ziv</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Belogolovski</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Barsheshet</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Bloch</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Uzan</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lahav</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Peretz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Frishman</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Progesterone increases bifidobacterium relative abundance during late pregnancy</article-title>. <source>Cell Rep</source>. <year>2019</year>;<volume>27</volume>(<issue>3</issue>):<fpage>730</fpage>&#x02013;<lpage>736.e733</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2019.03.075</pub-id>.<pub-id pub-id-type="pmid">30995472</pub-id>
</mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Paul</surname>
<given-names>HA</given-names></string-name>, <string-name><surname>Collins</surname>
<given-names>KH</given-names></string-name>, <string-name><surname>Bomhof</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Vogel</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Reimer</surname>
<given-names>RA</given-names></string-name></person-group>. <article-title>Potential impact of metabolic and gut microbial response to pregnancy and lactation in lean and diet&#x02010;induced obese rats on offspring obesity risk</article-title>. <source>Mol Nutr &#x00026; Food Res</source>. <year>2018</year>;<volume>62</volume>(<issue>4</issue>):<fpage>1700820</fpage>. doi: <pub-id pub-id-type="doi">10.1002/mnfr.201700820</pub-id>.</mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jiang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Qian</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>D</given-names></string-name></person-group>. <article-title>The gut microbiome during pregnancy</article-title>. <source>Maternal Fetal Med</source>. <year>2023</year>;<volume>5</volume>(<issue>1</issue>):<fpage>36</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">40406538</pub-id>
</mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dahl</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Stanislawski</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Iszatt</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Mandal</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Lozupone</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Clemente</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Knight</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Stigum</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Eggesb&#x000f8;</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Gut microbiome of mothers delivering prematurely shows reduced diversity and lower relative abundance of bifidobacterium and streptococcus</article-title>. <source>PLOS ONE</source>. <year>2017</year>;<volume>12</volume>(<issue>10</issue>):<fpage>e0184336</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0184336</pub-id>.<pub-id pub-id-type="pmid">29069100</pub-id>
</mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shiozaki</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yoneda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yoneda</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Yonezawa</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Matsubayashi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Seo</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Saito</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>Intestinal microbiota is different in women with preterm birth: results from terminal restriction fragment length polymorphism analysis</article-title>. <source>PLOS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>11</issue>):<fpage>e111374</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0111374</pub-id>.<pub-id pub-id-type="pmid">25372390</pub-id>
</mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>He</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>Y-E</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>Preterm birth is correlated with increased oral originated microbiome in the gut</article-title>. <source>Front Cell Infect Microbiol</source>. <year>2021</year>;<volume>11</volume>:<fpage>11</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fcimb.2021.579766</pub-id>.</mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aagaard</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Ganu</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Frias</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Takahashi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Petrosino</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Grove</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Versalovic</surname>
<given-names>J</given-names></string-name></person-group>. <article-title>A comprehensive metagenomic catalogue of microbiota across body sites in primates: a high fat maternal diters the offspring microbiome to 1 year of age</article-title>. <source>Am J Obstet Gynecol</source>. <year>2012</year>;<volume>206</volume>(<issue>1</issue>):<fpage>S30</fpage>.</mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Brotman</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Bradford</surname>
<given-names>LL</given-names></string-name>, <string-name><surname>Conrad</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Gajer</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ault</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Peralta</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Forney</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Carlton</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Abdo</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Ravel</surname>
<given-names>J</given-names></string-name>, et al</person-group>., <article-title>Association between trichomonas vaginalis and vaginal bacterial community composition among reproductive-age women</article-title>. <source>Sex Transm Dis</source>. <year>2012</year>;<volume>39</volume>(<issue>10</issue>):<fpage>807</fpage>&#x02013;<lpage>812</lpage>. doi: <pub-id pub-id-type="doi">10.1097/OLQ.0b013e3182631c79</pub-id>.<pub-id pub-id-type="pmid">23007708</pub-id>
</mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DiGiulio</surname>
<given-names>DB</given-names></string-name>, <string-name><surname>Callahan</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>McMurdie</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Costello</surname>, <given-names>EK</given-names></string-name>, <string-name><surname>Lyell</surname>, <given-names>DJ</given-names></string-name>, <string-name><surname>Robaczewska</surname>, <given-names>A</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>CL</given-names></string-name>, <string-name><surname>Goltsman</surname>, <given-names>DSA</given-names></string-name>, <string-name><surname>Wong</surname>, <given-names>RJ</given-names></string-name>, <string-name><surname>Shaw</surname>, <given-names>G</given-names></string-name>, et al</person-group>. <article-title>Temporal and spatial variation of the human microbiota during pregnancy</article-title>. <source>Proc Natl Acad Sci</source>. <year>2015</year>;<volume>112</volume>(<issue>35</issue>):<fpage>11060</fpage>&#x02013;<lpage>11065</lpage> doi:<pub-id pub-id-type="doi">10.1073/pnas.1502875112</pub-id>.<pub-id pub-id-type="pmid">26283357</pub-id>
</mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Balan</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Chong</surname>
<given-names>YS</given-names></string-name>, <string-name><surname>Umashankar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Swarup</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Loke</surname>
<given-names>WM</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>V</given-names></string-name>, <string-name><surname>He</surname>
<given-names>HG</given-names></string-name>, <string-name><surname>Seneviratne</surname>
<given-names>CJ</given-names></string-name></person-group>. <article-title>Keystone species in pregnancy gingivitis: a snapshot of oral microbiome during pregnancy and postpartum period</article-title>. <source>Front Microbiol</source>. <year>2018</year>;<volume>9</volume>. doi: <pub-id pub-id-type="doi">10.3389/fmicb.2018.02360</pub-id>.</mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saadaoui</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Al Khodor</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>Oral microbiome and pregnancy: a bidirectional relationship</article-title>. <source>J Reprod Immunol</source>. <year>2021</year>;<volume>145</volume>:<fpage>103293</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jri.2021.103293</pub-id>.<pub-id pub-id-type="pmid">33676065</pub-id>
</mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barak</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Oettinger-Barak</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Machtei</surname>
<given-names>EE</given-names></string-name>, <string-name><surname>Sprecher</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Ohel</surname>
<given-names>G</given-names></string-name></person-group>. <article-title>Evidence of periopathogenic microorganisms in placentas of women with preeclampsia</article-title>. <source>J Periodontol</source>. <year>2007</year>;<volume>78</volume>(<issue>4</issue>):<fpage>670</fpage>&#x02013;<lpage>676</lpage>. doi: <pub-id pub-id-type="doi">10.1902/jop.2007.060362</pub-id>.<pub-id pub-id-type="pmid">17397314</pub-id>
</mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dias</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pheiffer</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Adam</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>The maternal microbiome and gestational diabetes mellitus: cause and effect</article-title>. <source>Microorganisms</source>. <year>2023</year>;<volume>11</volume>(<issue>9</issue>):<fpage>2217</fpage>. doi: <pub-id pub-id-type="doi">10.3390/microorganisms11092217</pub-id>.<pub-id pub-id-type="pmid">37764061</pub-id>
</mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farr</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Sustr</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Kiss</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Rosicky</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Graf</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Makristathis</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Foessleitner</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Petricevic</surname>
<given-names>L</given-names></string-name></person-group>. <article-title>Oral probiotics to reduce vaginal group B streptococcal colonization in late pregnancy</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>19745</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-76896-4</pub-id>.<pub-id pub-id-type="pmid">33184437</pub-id>
</mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gille</surname>
<given-names>C</given-names></string-name>, <string-name><surname>B&#x000f6;er</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Marschal</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Urschitz</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Heinecke</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Hund</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Speidel</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tarnow</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Mylonas</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Franz</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Effect of probiotics on vaginal health in pregnancy. EFFPRO, a randomized controlled trial</article-title>. <source>Am J Obstet Gynecol</source>. <year>2016</year>;<volume>215</volume>(<issue>5</issue>):.<fpage>e608.601</fpage>&#x02013;<lpage>.e608.607</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajog.2016.06.021</pub-id>.</mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ho</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>Y-Y</given-names></string-name>, <string-name><surname>Chang</surname>
<given-names>W-C</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>H-C</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>M-H</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>W-C</given-names></string-name>, <string-name><surname>Chiu</surname>
<given-names>T-H</given-names></string-name></person-group>. <article-title>Oral lactobacillus rhamnosus GR-1 and lactobacillus reuteri RC-14 to reduce group B Streptococcus colonization in pregnant women: a randomized controlled trial</article-title>. <source>Taiwan J Obstet Gynecol</source>. <year>2016</year>;<volume>55</volume>(<issue>4</issue>):<fpage>515</fpage>&#x02013;<lpage>518</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tjog.2016.06.003</pub-id>.<pub-id pub-id-type="pmid">27590374</pub-id>
</mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olsen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Williamson</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Traynor</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Georgiou</surname>
<given-names>C</given-names></string-name></person-group>. <article-title>The impact of oral probiotics on vaginal group B streptococcal colonisation rates in pregnant women: a pilot randomised control study</article-title>. <source>Women Birth</source>. <year>2018</year>;<volume>31</volume>(<issue>1</issue>):<fpage>31</fpage>&#x02013;<lpage>37</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.wombi.2017.06.012</pub-id>.<pub-id pub-id-type="pmid">28668229</pub-id>
</mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mart&#x000ed;n</surname>
<given-names>V</given-names></string-name>, <string-name><surname>C&#x000e1;rdenas</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Oca&#x000f1;a</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mar&#x000ed;n</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Arroyo</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Beltr&#x000e1;n</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Badiola</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Fern&#x000e1;ndez</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Rodr&#x000ed;guez</surname>
<given-names>JM</given-names></string-name></person-group>. <article-title>Rectal and vaginal eradication of streptococcus agalactiae (GBS) in pregnant women by using lactobacillus salivarius CECT 9145, a target-specific Probiotic Strain</article-title>. <source>Nutrients</source>. <year>2019</year>;<volume>11</volume>(<issue>4</issue>):<fpage>810</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu11040810</pub-id>.<pub-id pub-id-type="pmid">30974819</pub-id>
</mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Milliano</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Tabbers</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>van der Post Ja</surname></string-name>, <string-name><surname>Benninga</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>van der Post</surname>
<given-names>JA</given-names></string-name></person-group>. <article-title>Is a multispecies probiotic mixture effective in constipation during pregnancy? A pilot study</article-title>. <source>Nutr J</source>. <year>2012</year>;<volume>11</volume>(<issue>1</issue>):<fpage>80</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1475-2891-11-80</pub-id>.<pub-id pub-id-type="pmid">23035837</pub-id>
</mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mirghafourvand</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Homayouni Rad</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Mohammad Alizadeh Charandabi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fardiazar</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Shokri</surname>
<given-names>K</given-names></string-name></person-group>. <article-title>The effect of probiotic yogurt on constipation in pregnant women: a randomized controlled clinical trial</article-title>. <source>Iran Red Crescent Med J</source>. <year>2016</year>;<volume>18</volume>(<issue>11</issue>):<fpage>e39870</fpage>. doi: <pub-id pub-id-type="doi">10.5812/ircmj.39870</pub-id>.<pub-id pub-id-type="pmid">28203450</pub-id>
</mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Husain</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Allotey</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Drymoussi</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Wilks</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fernandez&#x02010;Felix</surname>
<given-names>BM</given-names></string-name>, <string-name><surname>Whiley</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dodds</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Thangaratinam</surname>
<given-names>S</given-names></string-name>, <string-name><surname>McCourt</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Prosdocimi</surname>
<given-names>EM</given-names></string-name>, et al</person-group>. <article-title>Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis</article-title>. <source>BJOG</source>. <year>2020</year>;<volume>127</volume>(<issue>2</issue>):<fpage>275</fpage>&#x02013;<lpage>284</lpage>. doi: <pub-id pub-id-type="doi">10.1111/1471-0528.15675</pub-id>.<pub-id pub-id-type="pmid">30932317</pub-id>
</mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Asemi</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Esmaillzadeh</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Effect of daily consumption of probiotic yoghurt on serum levels of calcium, iron and liver enzymes in pregnant women</article-title>. <source>Int J Prev Med</source>. <year>2013</year>;<volume>4</volume>(<issue>8</issue>):<fpage>949</fpage>&#x02013;<lpage>955</lpage>.<pub-id pub-id-type="pmid">24049622</pub-id>
</mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Axling</surname>
<given-names>U</given-names></string-name>, <string-name><surname>G</surname>
<given-names>&#x000d6;</given-names></string-name>, <string-name><surname>Martinsson Niskanen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Larsson</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hansson</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Hulth&#x000e9;n</surname>
<given-names>L</given-names></string-name></person-group>. <article-title>The effect of Lactiplantibacillus plantarum 299v together with a low dose of iron on iron status in healthy pregnant women: a randomized clinical trial</article-title>. <source>Acta Obstet Gynecol Scand</source>. <year>2021</year>;<volume>100</volume>(<issue>9</issue>):<fpage>1602</fpage>&#x02013;<lpage>1610</lpage>. doi: <pub-id pub-id-type="doi">10.1111/aogs.14153</pub-id>.<pub-id pub-id-type="pmid">33880752</pub-id>
</mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Babadi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Khorshidi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Aghadavood</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Samimi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kavossian</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Bahmani</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mafi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shafabakhsh</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Satari</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Asemi</surname>
<given-names>Z</given-names></string-name>, et al</person-group>. <article-title>The effects of probiotic supplementation on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Probiotics Antimicrob Proteins</source>. <year>2019</year>;<volume>11</volume>(<issue>4</issue>):<fpage>1227</fpage>&#x02013;<lpage>1235</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12602-018-9490-z</pub-id>.<pub-id pub-id-type="pmid">30535534</pub-id>
</mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoppe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>G</surname>
<given-names>&#x000d6;</given-names></string-name>, <string-name><surname>Berggren</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hulth&#x000e9;n</surname>
<given-names>L</given-names></string-name></person-group>. <article-title>Probiotic strain lactobacillus plantarum 299v increases iron absorption from an iron-supplemented fruit drink: a double-isotope cross-over single-blind study in women of reproductive age</article-title>. <source>Br J Nutr</source>. <year>2015</year>;<volume>114</volume>(<issue>8</issue>):<fpage>1195</fpage>&#x02013;<lpage>1202</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S000711451500241X</pub-id>.<pub-id pub-id-type="pmid">26428277</pub-id>
</mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hoppe</surname>
<given-names>M</given-names></string-name>, <string-name><surname>G</surname>
<given-names>&#x000d6;</given-names></string-name>, <string-name><surname>Hulth&#x000e9;n</surname>
<given-names>L</given-names></string-name>, <string-name><surname>van Wouwe</surname>
<given-names>JP</given-names></string-name></person-group>. <article-title>Freeze-dried lactobacillus plantarum 299v increases iron absorption in young females&#x02014;double isotope sequential single-blind studies in menstruating women</article-title>. <source>PLOS ONE</source>. <year>2017</year>;<volume>12</volume>(<issue>12</issue>):<fpage>e0189141</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0189141</pub-id>.<pub-id pub-id-type="pmid">29236734</pub-id>
</mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jamilian</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Amirani</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Asemi</surname>
<given-names>Z</given-names></string-name></person-group>. <article-title>The effects of vitamin D and probiotic co-supplementation on glucose homeostasis, inflammation, oxidative stress and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Clin Nutr</source>. <year>2019</year>;<volume>38</volume>(<issue>5</issue>):<fpage>2098</fpage>&#x02013;<lpage>2105</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.clnu.2018.10.028</pub-id>.<pub-id pub-id-type="pmid">30459099</pub-id>
</mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaplas</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Isolauri</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lampi</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Ojala</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Laitinen</surname>
<given-names>K</given-names></string-name></person-group>. <article-title>Dietary counseling and probiotic supplementation during pregnancy modify placental phospholipid fatty acids</article-title>. <source>Lipids</source>. <year>2007</year>;<volume>42</volume>(<issue>9</issue>):<fpage>865</fpage>&#x02013;<lpage>870</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11745-007-3094-9</pub-id>.<pub-id pub-id-type="pmid">17647038</pub-id>
</mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>OjiNjideka Hemphill</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pezley</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Steffen</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Elam</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Kominiarek</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Odoms-Young</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kessee</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hamm</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Tussing-Humphreys</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Koenig</surname>
<given-names>MD</given-names></string-name>, et al</person-group>. <article-title>Feasibility study of lactobacillus plantarum 299v probiotic supplementation in an Urban Academic facility among diverse pregnant individuals</article-title>. <source>Nutrients</source>. <year>2023</year>;<volume>15</volume>(<issue>4</issue>):<fpage>875</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu15040875</pub-id>.<pub-id pub-id-type="pmid">36839232</pub-id>
</mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lindsay</surname>
<given-names>KL</given-names></string-name>, <string-name><surname>Brennan</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kennelly</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Maguire</surname>
<given-names>OC</given-names></string-name>, <string-name><surname>Smith</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Curran</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Coffey</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Foley</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Hatunic</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Shanahan</surname>
<given-names>F</given-names></string-name>, et al</person-group>. <article-title>Impact of probiotics in women with gestational diabetes mellitus on metabolic health: a randomized controlled trial</article-title>. <source>Am J Obstet Gynecol</source>. <year>2015</year>;<volume>212</volume>(<issue>4</issue>):<fpage>496.e491</fpage>&#x02013;<lpage>411</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajog.2015.02.008</pub-id>.</mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luoto</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Laitinen</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Nermes</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Isolauri</surname>
<given-names>E</given-names></string-name></person-group>. <article-title>Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study</article-title>. <source>Br J Nutr</source>. <year>2010</year>;<volume>103</volume>(<issue>12</issue>):<fpage>1792</fpage>&#x02013;<lpage>1799</lpage>. doi: <pub-id pub-id-type="doi">10.1017/S0007114509993898</pub-id>.<pub-id pub-id-type="pmid">20128938</pub-id>
</mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pellonper&#x000e4;</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Mokkala</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Houttu</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Vahlberg</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Koivuniemi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Tertti</surname>
<given-names>K</given-names></string-name>, <string-name><surname>R&#x000f6;nnemaa</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Laitinen</surname>
<given-names>K</given-names></string-name></person-group>. <article-title>Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an At-risk group of overweight and obese women: a randomized, placebo-controlled, double-blind clinical trial</article-title>. <source>Diabetes Care</source>. <year>2019</year>;<volume>42</volume>(<issue>6</issue>):<fpage>1009</fpage>&#x02013;<lpage>1017</lpage>. doi: <pub-id pub-id-type="doi">10.2337/dc18-2591</pub-id>.<pub-id pub-id-type="pmid">30967436</pub-id>
</mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reyes-Mu&#x000f1;oz</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Espino</surname></string-name> y <string-name><surname>Flores-Robles</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Sosa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Flores-Robles</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Mart&#x000ed;nez-Cruz</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Gardu&#x000f1;o-Garc&#x000ed;a</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Tawney-Serrano</surname>
<given-names>CR</given-names></string-name>, <string-name><surname>Dom&#x000ed;nguez-Rodr&#x000ed;guez</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Mart&#x000ed;nez-Hern&#x000e1;ndez</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>P&#x000e9;rez-Mota</surname>
<given-names>LR</given-names></string-name>, <string-name><surname>Llanes-Carrillo</surname>
<given-names>LC</given-names></string-name>, et al</person-group>. <article-title>Uso de mioinositol m&#x000e1;s Bifidobacterium lactis y Lactobacillus rhamnosus para la prevenci&#x000f3;n de diabetes mellitus gestacional en mujeres mexicanas</article-title>. <source>Gaceta M&#x000e9;dica de M&#x000e9;xico</source>. <year>2020</year>;<volume>156</volume>(<issue>93</issue>). doi: <pub-id pub-id-type="doi">10.24875/GMM.M20000438</pub-id>.</mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shahriari</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Karimi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Shahriari</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Aslani</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Khooshideh M</surname></string-name>, <string-name><surname>Arab</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: a parallel double-blind, randomized, placebo-controlled clinical trial</article-title>. <source>Biomed &#x00026; Pharmacother</source>. <year>2021</year>;<volume>141</volume>:<fpage>111915</fpage>.</mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Browne</surname>
<given-names>PD</given-names></string-name>, <string-name><surname>Bolte</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Besseling-van der Vaart</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Claassen</surname>
<given-names>E</given-names></string-name>, <string-name><surname>de Weerth</surname>
<given-names>C</given-names></string-name></person-group>. <article-title>Probiotics as a treatment for prenatal maternal anxiety and depression: a double-blind randomized pilot trial</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>3051</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-81204-9</pub-id>.<pub-id pub-id-type="pmid">33542275</pub-id>
</mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dawe</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Lme</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wilson</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Okesene-Gafa</surname>
<given-names>KAM</given-names></string-name>, <string-name><surname>Serlachius</surname>
<given-names>AS</given-names></string-name></person-group>. <article-title>Probiotics and maternal mental health: a randomised controlled trial among pregnant women with obesity</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>1291</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-020-58129-w</pub-id>.<pub-id pub-id-type="pmid">31992802</pub-id>
</mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hulkkonen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Kataja</surname>
<given-names>EL</given-names></string-name>, <string-name><surname>Vahlberg</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Koivuniemi</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Houttu</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Pellonper&#x000e4;</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Mokkala</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Karlsson</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Laitinen</surname>
<given-names>K</given-names></string-name></person-group>. <article-title>The efficacy of probiotics and/or n-3 long-chain polyunsaturated fatty acids intervention on maternal prenatal and postnatal depressive and anxiety symptoms among overweight and obese women</article-title>. <source>J Affect Disord</source>. <year>2021</year>;<volume>289</volume>:<fpage>21</fpage>&#x02013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jad.2021.04.006</pub-id>.<pub-id pub-id-type="pmid">33930612</pub-id>
</mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Slykerman</surname>
<given-names>RF</given-names></string-name>, <string-name><surname>Hood</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Wickens</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Thompson</surname>
<given-names>JMD</given-names></string-name>, <string-name><surname>Barthow</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Murphy</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rowden</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Stone</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Crane</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Effect of lactobacillus rhamnosus HN001 in pregnancy on postpartum symptoms of depression and anxiety: a randomised double-blind placebo-controlled trial</article-title>. <source>EBioMedicine</source>. <year>2017</year>;<volume>24</volume>:<fpage>159</fpage>&#x02013;<lpage>165</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ebiom.2017.09.013</pub-id>.<pub-id pub-id-type="pmid">28943228</pub-id>
</mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bayar</surname>
<given-names>E</given-names></string-name>, <string-name><surname>MacIntyre</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Sykes</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Mountain</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Parks</surname>
<given-names>TP</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>PP</given-names></string-name>, <string-name><surname>Bennett</surname>
<given-names>PR</given-names></string-name></person-group>. <article-title>Safety, tolerability, and acceptability of lactobacillus crispatus CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth</article-title>. <source>Benef Microbes</source>. <year>2023</year>;<volume>14</volume>(<issue>1</issue>):<fpage>45</fpage>&#x02013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.3920/BM2022.0084</pub-id>.<pub-id pub-id-type="pmid">36815494</pub-id>
</mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petricevic</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Rosicky</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Kiss</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Janjic</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Kaufmann</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Holzer</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Farr</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Effect of vaginal probiotics containing lactobacillus casei rhamnosus (Lcr regenerans) on vaginal dysbiotic microbiota and pregnancy outcome, prospective, randomized study</article-title>. <source>Sci Rep</source>. <year>2023</year>;<volume>13</volume>(<issue>1</issue>):<fpage>7129</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-34275-9</pub-id>.<pub-id pub-id-type="pmid">37130874</pub-id>
</mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Reid</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Challis</surname>
<given-names>JRG</given-names></string-name>, <string-name><surname>Gloor</surname>
<given-names>GB</given-names></string-name>, <string-name><surname>Asztalos</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Money</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Seney</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bocking</surname>
<given-names>AD</given-names></string-name></person-group>. <article-title>Effect of oral Probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the vaginal microbiota, cytokines and chemokines in pregnant women</article-title>. <source>Nutrients</source>. <year>2020</year>;<volume>12</volume>(<issue>2</issue>):<fpage>368</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu12020368</pub-id>.<pub-id pub-id-type="pmid">32019222</pub-id>
</mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aziz</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Spiegel</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bentley</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yoffe</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Klikoff</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ehrlich</surname>
<given-names>K</given-names></string-name>, <string-name><surname>El-Sayed</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Benitz</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Norton</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Taslimi</surname>
<given-names>MM</given-names></string-name>, et al</person-group>. <article-title>854: evaluation of probiotic oral supplementation effects on group B streptococcus rectovaginal colonization in pregnant women: a randomized double-blind placebo-controlled trial</article-title>. <source>Am J Obstet Gynecol</source>. <year>2018</year>;<volume>218</volume>(<issue>1</issue>):<fpage>S509</fpage>&#x02013;<lpage>S510</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajog.2017.11.391</pub-id>.</mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Babadi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Khorshidi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Aghadavood</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Samimi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kavossian</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Bahmani</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Mafi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Shafabakhsh</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Satari</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Asemi</surname>
<given-names>Z</given-names></string-name>, et al</person-group>. <article-title>The effects of probiotic supplementation on genetic and metabolic profiles in patients with gestational diabetes mellitus: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Probiotics Antimicrob Proteins</source>. <year>2019</year>;<volume>11</volume>(<issue>4</issue>):<fpage>1227</fpage>&#x02013;<lpage>1235</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12602-018-9490-z</pub-id>.<pub-id pub-id-type="pmid">30535534</pub-id>
</mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kami&#x00144;ska</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Stenclik</surname>
<given-names>D</given-names></string-name>, <string-name><surname>B&#x00142;a&#x0017c;ejewska</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Bogda&#x00144;ski</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Moszak</surname>
<given-names>M</given-names></string-name></person-group>. <article-title>Probiotics in the prevention and treatment of gestational diabetes mellitus (GDM): a review</article-title>. <source>Nutrients</source>. <year>2022</year>;<volume>14</volume>(<issue>20</issue>):<fpage>4303</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu14204303</pub-id>.<pub-id pub-id-type="pmid">36296986</pub-id>
</mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pakmehr</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ejtahed</surname>
<given-names>H-S</given-names></string-name>, <string-name><surname>Shirzad</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hemmatabadi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Farhat</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Larijani</surname>
<given-names>B</given-names></string-name></person-group>. <article-title>Preventive effect of probiotics supplementation on occurrence of gestational diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Front Med</source>. <year>2022</year>;<volume>9</volume>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2022.1031915</pub-id>.</mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>
<given-names>LS</given-names></string-name>, <string-name><surname>Ding</surname>
<given-names>CF</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Ng</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>N</given-names></string-name></person-group>. <article-title>Probiotics and synbiotics show clinical efficacy in treating gestational diabetes mellitus: a meta-analysis</article-title>. <source>Prim Care Diabetes</source>. <year>2021</year>;<volume>15</volume>(<issue>6</issue>):<fpage>937</fpage>&#x02013;<lpage>947</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pcd.2021.08.005</pub-id>.<pub-id pub-id-type="pmid">34417122</pub-id>
</mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Frishman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Nuriel-Ohayon</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Turjeman</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pinto</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yariv</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Tenenbaum-Gavish</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Peled</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Poran</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Pardo</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>R</given-names></string-name>, et al</person-group>. <article-title>Positive effects of diet-induced microbiome modification on GDM in mice following human faecal transfer</article-title>. <source>Gut</source>. <year>2024</year>;<volume>73</volume>(<issue>10</issue>):<fpage>gutjnl-2023</fpage>&#x02013;<lpage>331456</lpage>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2023-331456</pub-id>.</mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Desai</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Kozyrskyj</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Lau</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Sanni</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Dennett</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Walter</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Ospina</surname>
<given-names>MB</given-names></string-name></person-group>. <article-title>Effectiveness of probiotic, prebiotic, and synbiotic supplementation to improve perinatal mental health in mothers: a systematic review and meta-analysis</article-title>. <source>Front Psychiatry</source>. <year>2021</year>;<volume>12</volume>:<fpage>622181</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpsyt.2021.622181</pub-id>.<pub-id pub-id-type="pmid">33967849</pub-id>
</mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Halemani</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Shetty</surname>
<given-names>AP</given-names></string-name>, <string-name><surname>Thimmappa</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Issac</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Dhiraaj</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Radha</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mishra</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mathias</surname>
<given-names>EG</given-names></string-name></person-group>. <article-title>Impact of probiotic on anxiety and depression symptoms in pregnant and lactating women and microbiota of infants: a systematic review and meta-analysis</article-title>. <source>J Glob Health</source>. <year>2023</year>;<volume>13</volume>:<fpage>04038</fpage>. doi: <pub-id pub-id-type="doi">10.7189/jogh.13.04038</pub-id>.<pub-id pub-id-type="pmid">37218177</pub-id>
</mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jarde</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lewis-Mikhael</surname>
<given-names>A-M</given-names></string-name>, <string-name><surname>Moayyedi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Stearns</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Collins</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Beyene</surname>
<given-names>J</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>SD</given-names></string-name></person-group>. <article-title>Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis</article-title>. <source>BMC Pregnancy Childbirth</source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>14</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12884-017-1629-5</pub-id>.<pub-id pub-id-type="pmid">29310610</pub-id>
</mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baradwan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>AlSghan</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Sabban</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Khadawardi</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Abdelrahman Mohamed Ali</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Felemban</surname>
<given-names>LHA</given-names></string-name>, <string-name><surname>Khamis Galal</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ragab Rashed</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Salah Elsayed</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Mohammed Ibrahi</surname>
<given-names>E</given-names></string-name>, et al</person-group>. <article-title>Vaginal probiotics as an adjunct to antibiotic prophylaxis in the management of preterm premature rupture of membranes: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Eur J Obstet Gyn R B</source>. <year>2023</year>;<volume>291</volume>:<fpage>112</fpage>&#x02013;<lpage>119</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejogrb.2023.10.011</pub-id>.</mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Elias</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bozzo</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Einarson</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>Are probiotics safe for use during pregnancy and lactation?</article-title>
<source>Can Fam Phys</source>. <year>2011</year>;<volume>57</volume>:<fpage>299</fpage>&#x02013;<lpage>301</lpage>.</mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jarde</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lewis-Mikhael</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Moayyedi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Stearns</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Collins</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Beyene</surname>
<given-names>J</given-names></string-name>, <string-name><surname>McDonald</surname>
<given-names>SD</given-names></string-name></person-group>. <article-title>Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis</article-title>. <source>BMC Pregnancy Childbirth</source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>14</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12884-017-1629-5</pub-id>.<pub-id pub-id-type="pmid">29310610</pub-id>
</mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyle</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Robins-Browne</surname>
<given-names>RM</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>ML</given-names></string-name></person-group>. <article-title>Probiotic use in clinical practice: what are the risks?</article-title>
<source>Am J Clin Nutr</source>. <year>2006</year>;<volume>83</volume>(<issue>6</issue>):<fpage>1256</fpage>&#x02013;<lpage>1264</lpage>; <comment>quiz</comment>
<comment>1446-1257</comment>.<pub-id pub-id-type="pmid">16762934</pub-id>
</mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dugoua</surname>
<given-names>J-J</given-names></string-name>, <string-name><surname>Machado</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Koren</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Einarson</surname>
<given-names>TR</given-names></string-name></person-group>. <article-title>Probiotic safety in pregnancy: a systematic review and meta-analysis of randomized controlled trials of Lactobacillus, bifidobacterium, and saccharomyces spp</article-title>. <source>J Obstet Gynaecol Canada</source>. <year>2009</year>;<volume>31</volume>(<issue>6</issue>):<fpage>542</fpage>&#x02013;<lpage>552</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1701-2163(16)34218-9</pub-id>.</mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Doron</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Snydman</surname>
<given-names>DR</given-names></string-name></person-group>. <article-title>Risk and safety of probiotics</article-title>. <source>Clin Infect Dis: Off Publ Infect Dis Soc Am</source>. <year>2015</year>;<volume>602</volume>(<issue>Suppl 2</issue>):<fpage>S129</fpage>&#x02013;<lpage>134</lpage>.</mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prescott</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Bj&#x000f6;rkst&#x000e9;n</surname>
<given-names>B</given-names></string-name></person-group>. <article-title>Probiotics for the prevention or treatment of allergic diseases</article-title>. <source>J Allergy Clin Immunol Pract</source>. <year>2007</year>;<volume>120</volume>(<issue>2</issue>):<fpage>255</fpage>&#x02013;<lpage>262</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaci.2007.04.027</pub-id>.</mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Simpson</surname>
<given-names>MR</given-names></string-name>, <string-name><surname>Dotterud</surname>
<given-names>CK</given-names></string-name>, <string-name><surname>Storr&#x000f8;</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Johnsen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>&#x000d8;ien</surname>
<given-names>T</given-names></string-name></person-group>. <article-title>Perinatal probiotic supplementation in the prevention of allergy related disease: 6 year follow up of a randomised controlled trial</article-title>. <source>BMC Dermatol</source>. <year>2015</year>;<volume>15</volume>(<issue>1</issue>):<fpage>13</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12895-015-0030-1</pub-id>.<pub-id pub-id-type="pmid">26232126</pub-id>
</mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zmora</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Zilberman-Schapira</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Suez</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Mor</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Dori-Bachash</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bashiardes</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kotler</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zur</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Regev-Lehavi</surname>
<given-names>D</given-names></string-name>, <string-name><given-names>Brik</given-names>
<surname>RB</surname></string-name>, <string-name><surname>Federici</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features</article-title>. <source>Cell</source>. <year>2018</year>;<volume>174</volume>(<issue>6</issue>):<fpage>1388</fpage>&#x02013;<lpage>1405.e1321</lpage>.<pub-id pub-id-type="pmid">30193112</pub-id>
</mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Di Simone</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Santamaria Ortiz</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Specchia</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tersigni</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Villa</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Gasbarrini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scambia</surname>
<given-names>G</given-names></string-name>, <string-name><surname>D&#x02019;Ippolito</surname>
<given-names>S</given-names></string-name></person-group>. <article-title>Recent insights on the maternal microbiota: impact on pregnancy outcomes</article-title>. <source>Front Immunol</source>. <year>2020</year>;<volume>11</volume>:<fpage>528202</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2020.528202</pub-id>.<pub-id pub-id-type="pmid">33193302</pub-id>
</mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xiao</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>F</given-names></string-name></person-group>. <article-title>Microbial transmission, colonisation and succession: from pregnancy to infancy</article-title>. <source>Gut</source>. <year>2023</year>;<volume>72</volume>(<issue>4</issue>):<fpage>772</fpage>&#x02013;<lpage>786</lpage>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2022-328970</pub-id>.<pub-id pub-id-type="pmid">36720630</pub-id>
</mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cobb</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Kelly</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>KB</given-names></string-name>, <string-name><surname>Babbar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Angolkar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Derman</surname>
<given-names>RJ</given-names></string-name></person-group>. <article-title>The oral microbiome and adverse pregnancy outcomes</article-title>. <source>Int J Multiling women&#x02019;s Health</source>. <year>2017</year>;<volume>2017</volume>:<fpage>551</fpage>&#x02013;<lpage>559</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IJWH.S142730</pub-id>.</mixed-citation></ref></ref-list></back></article>